Neurobiology of Disease 48 (2012) 255–270
Contents lists available at SciVerse ScienceDirect
Neurobiology of Disease
journal homepage: www.elsevier.com/locate/ynbdi
Review
Gene therapy for the treatment of chronic peripheral nervous system pain
William F. Goins ⁎, Justus B. Cohen, Joseph C. Glorioso
Dept of Microbiology & Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh PA 15219, USA
a r t i c l e
i n f o
Article history:
Received 25 August 2011
Revised 11 May 2012
Accepted 24 May 2012
Available online 2 June 2012
Keywords:
Gene therapy
Viral vectors
Neuropathic pain
Nociceptive pain
Peripheral nervous system
Spinal cord
Animal models
Herpes simplex virus
Lentivirus
Retrovirus
Adenovirus
Adeno-associated virus
Plasmid DNA
Enkephalin
Endorphin
Glutamic acid decarboxylase
Interleukins
Neurotransmitters
Neurotrophins
a b s t r a c t
Chronic pain is a major health concern affecting 80 million Americans at some time in their lives with significant
associated morbidity and effects on individual quality of life. Chronic pain can result from a variety of inflammatory
and nerve damaging events that include cancer, infectious diseases, autoimmune-related syndromes and surgery.
Current pharmacotherapies have not provided an effective long-term solution as they are limited by drug tolerance
and potential abuse. These concerns have led to the development and testing of gene therapy approaches to treat
chronic pain. The potential efficacy of gene therapy for pain has been reported in numerous pre-clinical studies
that demonstrate pain control at the level of the spinal cord. This promise has been recently supported by a
Phase-I human trial in which a replication-defective herpes simplex virus (HSV) vector was used to deliver the
human pre-proenkephalin (hPPE) gene, encoding the natural opioid peptides met- and leu-enkephalin (ENK), to
cancer patients with intractable pain resulting from bone metastases (Fink et al., 2011). The study showed that
the therapy was well tolerated and that patients receiving the higher doses of therapeutic vector experienced a substantial reduction in their overall pain scores for up to a month post vector injection. These exciting early clinical results await further patient testing to demonstrate treatment efficacy and will likely pave the way for other gene
therapies to treat chronic pain.
© 2012 Elsevier Inc. All rights reserved.
Contents
Introduction . . . . . . . . . . . . . . . . . . . . . . . .
Nature of the chronic pain state . . . . . . . . .
Current therapies for the treatment of chronic pain
Non-viral and viral vectors for the treatment of chronic pain .
Non-viral based plasmid vectors . . . . . . . . .
Virus-based vectors . . . . . . . . . . . . . . .
Retrovirus-based vectors . . . . . . . .
Lentivirus-based vectors . . . . . . . . .
Adenovirus-based vectors . . . . . . . .
Adeno-associated virus-based vectors . .
Herpes simplex virus-based vectors . . .
Gene therapy approaches for the treatment of chronic pain . .
Neurotrophic/growth factor gene therapy . . . . .
Opioid peptide gene therapy . . . . . . . . . . .
⁎ Corresponding author. Fax: + 1 4126489461.
E-mail address: goins@pitt.edu (W.F. Goins).
Available online on ScienceDirect (www.sciencedirect.com).
0969-9961/$ – see front matter © 2012 Elsevier Inc. All rights reserved.
doi:10.1016/j.nbd.2012.05.005
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
256
256
257
258
258
259
259
259
261
261
261
263
263
263
256
W.F. Goins et al. / Neurobiology of Disease 48 (2012) 255–270
Neurotransmitter-based gene therapy . . . .
Immuno-modulatory molecule gene therapy .
Anti-sense-based gene therapy . . . . . . .
TRPV1 modulator gene therapy . . . . . . .
Clinical gene therapy trials for pain. . . . . . . . . . .
Summary and future directions . . . . . . . . . . . .
Acknowledgments . . . . . . . . . . . . . . . . . .
References . . . . . . . . . . . . . . . . . . . . . .
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
Introduction
Pain is one of the most prevalent disease complications and is now included as the fifth vital sign by most hospitals. It is estimated that 60–
80 million patients within the US suffer from some form of chronic
pain. As defined by the International Association for the Study of Pain,
chronic pain is a severe and ever-present pain that persists for at least
3 months post initial injury or tissue damage. Chronic pain is often debilitating, leading to substantial loss of productivity and impaired quality of
life. In 2005, chronic back and neck pain affected 22 million patients creating an estimated $86 billion in health care expenditures (Martin et al.,
2009). Arthritis, another common cause of chronic pain, is predicted to affect 25% of the adult population by the year 2030, with 25 million
experiencing activity limitations resulting from chronic pain (Hootman
and Helmick, 2006). The societal burden from chronic pain patients will
continue to increase as the population ages.
Nature of the chronic pain state
Chronic pain can result from inflammation and nerve damage. Nociceptive pain of an inflammatory nature is associated with a typical
immune response to tissue injury or infection whereas neuropathic
pain results from damage to neural structures, often in the absence
of accompanying injury to non-neural tissues. Nociceptive pain is
quite common and results from a variety of disease states in which
short-term or long-term inflammation leads to prolonged changes
in nociception. The most common incidence occurs in patients with
rheumatoid or osteoarthritis, pancreatitis, or inflammatory bowel disease. Other associated conditions include interstitial cystitis (IC) or
chronic pelvic pain syndrome of the bladder. Common immune
mediators, such as the inflammatory cytokines interleukin-1 (IL-1),
IL-6 and tumor necrosis factor-alpha (TNFα), contribute to a localized
inflammatory response in the afflicted tissue or organ. They act to
induce the mobilization of immune cells that amplifies their production
and results in prolonged painful responses (Moalem and Tracey, 2006).
The same pro-inflammatory cytokines are also secreted by glia within
the spinal cord and astrocytes in response to peripheral organ and tissue inflammation, which impacts the nociceptive processes in the spinal cord (Moalem and Tracey, 2006; Sloane et al., 2009). Animal
models of acute and chronic nociceptive pain have been created by injection of (i) immunogenic substances, including complete Freund's adjuvant (CFA), carrageenan and LPS, (ii) chemicals such as formalin,
capsaicin, or dibutyltin dichloride, or (iii) acids like monoiodoacetate
to create a model of monoarthritis or acetic acid to induce lower urinary
tract pain in rats.
Neuropathic or neurogenic pain is defined as pain initiated or caused by a primary lesion or dysfunction of the nervous system. This can
be the result of (i) spinal cord injury (SCI), (ii) peripheral nerve
damage resulting from diabetes or other autoimmune diseases, (iii)
treatment with anti-cancer drugs that affect axon integrity, or (iv)
post-herpetic neuralgia (PHN). A variety of animal models mimic
neuropathic pain: (i) surgical models of nerve damage, including
chronic constriction injury (CCI) and spared nerve injury (SNI), (ii)
streptozotocin-induced painful diabetic neuropathy and transgenic
diabetic pain models, (iii) treatment with anti-cancer drugs and
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
264
265
265
266
266
266
268
268
models of bone cancer pain established by introduction of sarcoma
cells into the femur (Goss et al., 2002; Lan et al., 2010), and (iv)
PHN induced by footpad injection of HSV (Kuraishi et al., 2004;
Takasaki et al., 2001) or VZV (Garry et al., 2005; Hasnie et al., 2007).
The first event in pain signaling in response to inflammatory and/or
mechanical damage to peripheral tissues/organs is an increase in the extracellular levels of mediators such as bradykinin, substance P (SP), ATP,
hydrogen ions, histamine, prostaglandins and inflammatory cytokines
such as TNFα and IL-1. It is likely that besides the peripheral signals
which can induce the chronic pain response, central signals may also
lead to the establishment of chronic pain, both centrally and also can
manifest itself as peripheral chronic pain. The inflammatory cytokines
and prostaglandins are secreted by inflammatory cells, such as resident
mast cells and macrophages recruited to the initial insult via mast cellreleased cytokines, or Schwann cells and microglia that are local to the
site of nerve damage (Moalem and Tracey, 2006). Release of these molecules by the damaged tissue results in ‘peripheral sensitization,’ i.e. stimulation of primary afferents via specific receptors or ion channels
sensitive to heat, mechanical impulses, protons, or cold. These stimuli activate second messenger systems, including protein kinases A and C,
which results in ectopic discharge due to increased sensitivity of endogenous voltage-gated sodium and calcium channels leading to hyperalgesia,
a heightened response to painful stimuli, and allodynia, pain in response
to normally non-painful stimuli (Julius and Basbaum, 2001; Scholz and
Woolf, 2002). In addition, the increased levels of intracellular calcium
can lead to the release of neuropeptides such as SP, CGRP and neurokinin
A from vesicles at the cell termini; extracellular accumulation of these factors increases their receptor occupancy in the damaged tissue, thereby
amplifying the pain signal. These stimulated afferent nerve fibers carry
impulses to second order neurons located within the dorsal horn of the
spinal cord, the site where control and processing of the initial nociceptive signal takes place.
Pain usually occurs in two phases. The first is sharp in intensity,
short in duration, very focal in nature, and is mediated by Aδafferents that display firing rates that correlate with the intensity of
the painful stimulus. In contrast, the second phase is rather dull in intensity, displays a more prolonged duration, is not localized in nature,
and is mediated by unmyelinated C-fiber afferents that display a progressive increase in their discharge rate toward second order neurons
in the spinal cord (Woolf, 1996). These second-order neurons,
projecting centrally to the thalamus, the dorsal reticular nucleus
and periaqueductal gray, ultimately relay the signal to the cortex enabling pain perception. In addition, there are descending signaling
pathways from the brain back down to the dorsal horn of the spinal
cord where release of endogenous opioid peptides such as the enkephalins, ß-endorphin, dynorphins and endomorphin occurs as the
body's natural pain management response (Basbaum and Fields,
1984). Chronic pain is a result of continuous or altered signaling within the activation loop. Additionally, proinflammatory agents such as
prostaglandin E2, serotonin, histamine and adenosine, and neurotrophic factors such as NGF, can induce functional changes in C-fiber
afferents that can lead to hyperactivation or hyperexcitability of relatively unexcitable afferents (Gold et al., 1996). Although pain can
manifest itself both centrally, such as headache, or peripherally,
such as arthritis or lower back pain, this review will concentrate
W.F. Goins et al. / Neurobiology of Disease 48 (2012) 255–270
only on the use of gene therapy approaches to treat peripheral forms
of pain. However, many of the therapies discussed represent efforts to
block pain signaling and thus are directed to treatment at the level of
the spinal cord mostly via the expression of immune modulatory gene
products that alter the host response in the case of nociceptive pain.
Current therapies for the treatment of chronic pain
Therapies for chronic pain tend to be complex as they must deal
with the insult that initiates the pain response, the conditions that
cause the transition from acute to chronic pain, and finally the factors
that maintain the chronic state. Surgical intervention and drug therapies have been employed to treat chronic pain, but have generally
met with limited success. Surgery has proven effective for some
forms of chronic lower back or neck pain, but is rarely used to treat
lower urinary tract pain, for example. For patients with osteoarthritis,
surgical intervention may initially result in reduced pain but many of
these patients eventually develop rheumatoid arthritis for which surgery is not typically prescribed. Electrical device neuromodulatory
strategies that send low to high frequency modulatory impulses to
the nerves involved in pain signaling using external devices, like the
transcutaneous electric nerve stimulation unit, have proved effective
for some patients with painful diabetic neuropathy and pain resulting
from neoplasia, but have not proven successful for patients with
chronic back and neck pain (Dubinsky and Miyasaki, 2010). Overall,
the ability of these electrical devices to reduce chronic pain seems
to be linked to the frequency employed, as lower frequency treatments display a higher failure rate than treatment at high frequency
(Bennett et al., 2011). Two types of drug-mediated nerve blocks
have been employed for chronic pain treatment. Trigger point injections are more local and usually involve injection of either local anesthetics or extended duration corticosteroids, while peripheral nerve
block injections affect body regions. These treatment regimens have
helped patients suffering from chronic pain of musculoskeletal origin,
including lower back pain, whiplash, myofascial pain, and fibromyalgia. However, patients with other forms of nociceptive and neuropathic chronic pain have been refractory to these approaches.
Of all interventions for chronic pain, NSAIDs (Advil, Motrin,
Aleve), other analgesics (Tylenol, Aspirin), adjuvant analgesics, and
opioid analgesics are the most frequently prescribed therapies
(Toblin et al., 2011). NSAIDs are the recommended first-line drugs
employed in chronic pain treatment to reduce the inflammatory component via inhibition of cyclooxygenase, leading to a block in nociceptive signaling either at the peripheral site of injury/inflammation or
within the dorsal horn of the spinal cord. The efficacy of NSAID and
other non-opioid analgesic treatments is usually transient and thus
these drugs are most effective against acute pain. As they are targeted
at inflammatory mechanisms, they lack consistent efficacy against
severe or moderate chronic pain, and additionally display unwanted
side effects associated with the higher doses needed to effectively
block the pain response, such as gastrointestinal and renal toxicities.
However, the overall efficacy of these non-opioid analgesics
can be dramatically improved by the inclusion of adjuvant analgesics, a group of drugs consisting of (i) tricyclic antidepressants
such as amytriptyline, (ii) anti-epileptic drugs like carbamazepine,
gabapentin and pregabalin, (iii) γ-aminobutyric acid (GABA) agonists
such as baclofen, and (iv) NMDA agonists including ketamine,
amantidine, dextromethorphan and memantine (Chou et al., 2009).
Although adjuvant analgesics also show some signs of tolerance or
risk of addiction like the opioid analgesics, they also however frequently demonstrate organ or tissue toxicities, have a narrow therapeutic window, display a ceiling effect, and generally have a
sedative effect making their use in chronic pain patients with active
lifestyles undesirable.
The second line of drugs includes the less potent opioid analgesics
such as tramadol (Ultram), codeine, and hydrocodone (Vicodin), with
257
or without adjuvant analgesics. They are used to treat moderate
forms of chronic pain (Chou et al., 2009). The final option drugs include the potent opioids, such as morphine, methadone, levorphanol,
oxycodone and fentanyl, for use against moderate to very severe
chronic pain, again with or without adjuvant analgesics. The use of
such prescription opioid analgesics has increased by an order of magnitude over the last 10–15 years (Ling et al., 2011), with as much as
4% of the total USA population now using opioids (Toblin et al.,
2011). Hydrocodone alone was prescribed over 128 million times in
2008 (Younger et al., 2011), making it the most dispensed drug in
the US ahead of lipid-regulating drugs like atorvastatin, rosuvastatin
and gemfibrozil. Although the opioids display good toxicity profiles,
they suffer from the complications of tolerance (i.e. dependence/addiction), abuse, and misuse/diversion. Addiction and abuse rates are
low in individuals with moderate to severe chronic pain that have
been prescribed opioids, but as these drugs have become more readily available, their abuse and addiction rates in the general population
continue to rise (Fishbain et al., 2008).
Because opioid and non-opioid based drug therapies are efficacious in only 10–60% of patients suffering from chronic pain (Chou
et al., 2009; Ling et al., 2011; Toblin et al., 2011) and risk the complications of addiction, abuse, tolerance and side effects such as nausea,
constipation and toxicities associated with drug interactions, novel
therapeutics for chronic pain are needed. Research into cell-based
transplantation therapies was initiated in order to develop a novel
non-pharmaceutical approach to treating chronic pain. The first studies employed adrenal chromaffin cells that naturally express catecholamines, met- and leu-ENK, as well as neurotrophic factors such
as BDNF and NGF (Sol et al., 2005). Intrathecal (i.t.) transplantation
of these cells into the subarachnoid space in formalin, SNL, CCI, cancer
and arthritic pain models showed encouraging results as the grafts
simply appeared to function as mini-pumps secreting their mediators
into the dorsal of the spinal cord (Sol et al., 2005). However, some
studies reported limited efficacy (Lindner et al., 2003). Two major
concerns regarding the use of these cell grafts is that their uncontrolled growth may lead to tumor formation and that the host will
mount an immune response that leads to clearance of the graft. Attempts to address the second concern with microencapsulated grafts
showed that these grafts were able to both secrete catecholamines
and ENK and reduce thermal hyperalgesia and mechanical allodynia
levels, but their survival after 1 month was poor (Kim et al., 2009c).
In addition, numerous groups have employed a variety of immortalized neuronal cells (NT2, NB69, AtT-20, RN33B, RN46A, and P19) or
primary cells such as astrocytes or macrophages, transduced with either hPPE (Hino et al., 2009), POMC (Beutler et al., 1995), BDNF
(Eaton et al., 1997), GAD (Eaton et al., 1999), or galanin (An et al.,
2010) in cell transplant models for treating chronic pain. Again, the
tumorigenic and immunogenic potential of these grafts, as well as
their viability and continued release of anti-nociceptive products,
represent concerns that will make the transition of these preclinical studies into human clinical trials difficult, underscoring the
need for further alternatives.
Gene therapy represents a novel and targeted approach for
treating chronic pain. The process employs both non-viral and viral
gene transfer vectors to deliver genes encoding such candidate
therapeutic products as natural opiates (ENK, POMC), effectors
of neurotransmitter synthesis (GAD, Glut-1), neurotrophins or
growth factors (NGF, BDNF, GDNF, VEGF, EPO, FGF2, HGF), immune
modulatory factors (IL-10, IL-2, IL-4, TNFαsR, Iκβ), or anti-sense
RNA to genes believed to play a role in the pain response. Many, if
not all, of the cDNAs for these products are small enough in size to
be readily incorporated into existing gene transfer vectors. In vivo
gene transfer derives specificity from injection of the vectors directly
into the target site or injection into peripheral tissues where natural
transport mechanisms exist for bringing the vector to the target neurons or glia involved in pain modulation within the PNS. Viral vectors
258
W.F. Goins et al. / Neurobiology of Disease 48 (2012) 255–270
for pain therapy utilize highly efficient mechanisms for transduction
of neurons and glia as part of their natural biology, suggesting that
sufficient numbers of cells can be transduced to achieve high levels
of anti-nociceptive gene expression and attendant anti-nociceptive
effects. Additionally, these gene therapeutic approaches can be combined with standard drug, physical therapy and surgical approaches
to increase the overall chance of success. Since the vectors typically
deliver natural gene products, the likelihood of generating tolerance
or a significant immune response to the therapeutic product is minimal. However, several potential problems exist for the different nonviral and viral vector methodologies listed in Table 1 and discussed in
the upcoming section, including (i) immunogenicity of the vector,
(ii) vector toxicity, (iii) tumor formation as a result of viral genome
integration into the host genome, (iv) cost and ease of vector production and purification, (v) overall vector safety in humans, and
(vi) secondary immune responses elicited by vector re-administration.
Non-viral and viral vectors for the treatment of chronic pain
A number of methods have been tested for the delivery of nonviral plasmids to treat pain, such as injection of naked plasmid DNA,
liposome- or nanoparticle-mediated delivery, and physical methods
including ultrasound, electroporation, and gene gun technology.
However, the most widely studied gene therapy approaches have
used viral vectors for gene delivery. Viral vector gene therapy takes
advantage of the natural ability of viruses to infect cells and have
their genomes transported to the nucleus where their payload
genes can be expressed. Viral vector systems can express transgenes
for various durations, including prolonged periods of time, and
some systems can express multiple genes at once or exceptionally
large genes. Additionally, methods now exist to restrict or redirect
the infectivity of viral vectors to specific cell types by altering viral
surface proteins for exclusive recognition of target cell-specific
receptors. Many of these vectors can be injected peripherally from
where they will travel via retrograde axonal transport to the DRGs
or motor neurons that innervate the site of injection. These same
axonal transport mechanisms provide for the efficient delivery of
viral genomes to the nucleus where transgene expression takes
place. Although there are many different recombinant viral vector
systems under development today for the treatment of a variety
of experimental conditions, and some of these are in clinical trials,
this chapter focuses on the systems that have been employed to
treat chronic pain. These are based on adenovirus (AdV) [23.8%
of published pain gene therapy studies according to statistics for
2010 http://www.wiley.com/legacy/wileychi/genmed/clinical/], retroviruses (RV) [20.5%], adeno-associated virus (AAV) [4.5%], herpes
simplex virus (HSV) [3.3%], and lentiviruses (LV) [1.7%] (Davidson
and Breakefield, 2003; Lotze and Kost, 2002); non-viral delivery systems listed include naked [17.7%] or liposome-encapsulated plasmid
DNA [6.5%]. Each of these viral and non-viral vector systems has advantages and disadvantages, as summarized in Table 1. One important distinction between the different viral vectors is their ability to
persist long-term and provide a sustained effect suitable for the treatment of chronic pain. Since the AdV vectors do not persist long-term,
they are not ideal for the treatment of long-term chronic pain. The
viral vectors that persist long-term can be further divided into two
groups, those that integrate into the host genome (RV, LV, AAV) and
those that persist long-term as non-integrated episomes (HSV, AAV).
Non-viral based plasmid vectors
Methods to deliver naked plasmid DNA into cells are among the
simplest to achieve foreign gene expression in cells. Since they do
not involve extraneous substances, the only possible chance of generating a host immune response is to the naked plasmid DNA itself via
activation of toll-like receptors. However, the current methods for
naked DNA delivery yield low transduction efficiencies, and although
relatively cell-specific gene-control elements can be included, transductional specificity remains limited (Ledley, 1995). Another inherent problem with naked DNA vectors is the short duration of
Table 1
Gene delivery vectors.
Vector
Plasmid
RV
LV
AdV
AAV
HSV
1) Genome size
2) Payload size
(a) Size
(b) Genes
3) Host range
(a) Dividing
(b) Non-dividing
4) Transduction efficiency
Varies
Varies
Varies
Varies
Varies
+
+/−
Low
~ 10 kb
++
~ 7 kb
1–2
Limited
+
−
High
~ 10 kb
++
~ 6.5 kb
1–2
Limiteda
+
+
High
~ 40 kb
+++
~ 7–36 kb
1–many
Broad
+
+
Med (102–103)
~ 5 kb
+
~ 3–4.5 kb
1
Broad
+
+
Low–med (103–105)
5) Genome stability
(a) Episomal
(b) Integrated
6) Transgene expression
(a) Short-term
(b) Long-term
7) Production
(a) Cell lines
(b) Kits
(c) Cost
8) Titers (TU/mL)
9) Safety
(a) Tumors
(b) Recomb.
(c) IR
(d) Cytotoxicity
10) Repeat Dosing
Low
+
+/−
Med
+
−
Easy
−
+
High
High
−
++
Med
+
++
Easy
+
+
Low
105–107
+/−
++
++
−
−
+/−
High
−
++
Med
+
++
Easy
+
+
Low
106–108
+/−
++
++
−
−
+/−
Low
++
−
High
+++
−
Easy
+
+
Low
1010–1013
−
−
+
+++++
+++
−
High
+
++
Med
+
++
Easy–hard
+
+
Med
108–1012
++/−
+/−
+
+++
−
− (Eye+)c
~ 150 kb
++++
~ 40 kb +
1–many
Broad
+
+
High
(1–10)
Med–high
+++
−
Med
++
+/−
Hard
+
−
Low
109–1011
+
−
+/−
+/−
++/−
++
b
+++
−
−
++
+/−
+
Abbreviations: AAV, adeno-associated virus; AdV, adenovirus; HSV, herpes simplex virus; IR, immune response; kb, kilobase; LV, lentivirus; mL, milliliters; RV, retrovirus; TU, transducing units.
a
Host range of pseudotyped LV varies with the glycoproteins employed which affects transduction efficiency.
b
Plasmid DNA preparations in mg/mL rather than TU/mL.
c
AAV repeat dosing has been achieved during vector delivery to the eye/retina.
W.F. Goins et al. / Neurobiology of Disease 48 (2012) 255–270
transgene expression that is probably the combined result of poor
transduction efficiency, low stability and persistence of the DNA,
and a surprisingly strong host response to DNA. Modifications such
as packaging the plasmid DNA into liposomes have shown lower immunogenicity, a higher level of transgene expression and increased
(40×) transduction efficiency (Shi et al., 2003), including of DRG
neurons following intrathecal injection (Wang et al., 2005), but expression has remained short term (Shi et al., 2003). Further improvements in transduction efficiencies have been seen with incorporation
of the plasmid DNA into nanoparticles, but immunogenicity was variable, most likely depending on the nature of the material used to
construct the nanoparticles (Belyanskaya et al., 2009). Among the
physical techniques, electroporation of a recombinant plasmid
encoding the natural opioid ß-endorphin resulted in expression in
the rodent PNS and reduced mechanical allodynia pain measurements (Chen et al., 2008; Lin et al., 2002). Others have employed
the gene gun (Chuang et al., 2003) or shockwaves (Yamashita et al.,
2009) to increase the delivery of naked plasmid DNA to DRG and spinal cord neurons for treating pain. Collectively, while these physical
delivery methods have shown increased in vitro transduction efficiencies of primary DRG neurons in culture, this enhancement has
not been reproduced in vivo (Lin et al., 2010). A recent report
(Machelska et al., 2009) employed a non-viral, non-plasmid, immunologically defined gene expression vector to treat CFA-induced
chronic nociceptive pain that showed improved transduction compared with previous reports. In order to increase the specificity of
non-viral gene delivery methods, NGF peptides have been used to
promote binding of naked DNA complexes to TrkA-positive DRG neurons (Zeng et al., 2007) and a fragment of the tetanus toxin non-toxic
subunit has been used to target the tetanus toxin receptor on DRG
neurons (Oliveira et al., 2010). These modifications achieved increased transduction of DRG compared to non-neuronal cells. However, despite improvements in transduction efficiency and specificity
achieved by current plasmid delivery methods, viral vectors have
generally proven superior for gene delivery in vivo, especially to
PNS neurons.
Virus-based vectors
Viral vectors provide efficient tools for gene transfer to the nervous system. Upon receptor-assisted virus entry into the cell, the
viral genome is generally transported to the nucleus where it can express its resident genes, including its payload transgenes. In the case
of PNS neurons, viral nucleocapsids are transported by cytoplasmic
molecular motors from their point of entry at the nerve termini to
the nerve cell body by retrograde axonal transport where their genomes are injected into nucleus. Viruses have evolved complex
mechanisms that help them evade both innate and adaptive host
cell immunity, important features to help ensure successful transduction and expression of therapeutic gene products. Many viruses are
capable of persisting long-term in neurons of the PNS, either in the
form of episomes (HSV, AAV) or by integration of their genome into
host cell chromosomes (RV, LV, AAV) and can be provided with promoter systems capable of durable transgene expression. Although
AdV vector genomes are found as non-integrated episomes, they do
not persist for extended times so this class of vector is better suited
to acute pain approaches yet has been used in some gene therapy
approaches.
Retrovirus-based vectors
Retroviral (RV) vectors were used in the first gene transfer studies
performed with cells in culture that were then transplanted back into
animals in an ex vivo gene therapy approach. Retroviruses are
enveloped viruses that contain an encapsidated dsRNA genome
encoding the capsid (gag) and envelope glycoprotein (env) structural
components of the virus and a reverse transcriptase (pol) (Fig. 1).
259
Upon binding to their natural cell surface receptors, RVs enter the
cell primarily by envelope fusion with the cell surface membrane although they can also enter by endocytosis. The size of RV genomes
is limited by packaging contraints, allowing the incorporation of just
1–2 small transgenes (Table 1) by replacement of the structural and
enzymatic genes of the virus (Fig. 1). Vectors expressing therapeutic
or reporter genes can be readily generated by transfection of recombinant vector constructs into packaging cell lines that express the enzymatic and structural viral genes required for the production of new
RV vector particles, but lack the RV packaging signal (Ψ). Transgenes
can be expressed from the native RV promoter in the viral long terminal repeat (LTR), from other strong promoters such as the HCMV
major immediate early promoter, or from cell-specific promoters.
The great majority of early gene therapy clinical trials used RV
vectors based on the fact that they are easy to construct and produce
with the availability of an abundance of stable packaging cell lines,
display good transduction efficiencies, and yield long-term stable
transgene expression as the RV genome integrates into the host
DNA as part of its natural life-cycle. Although RV vectors are not immunogenic and display high therapeutic efficacy, approaches using
these vectors have been hampered by two significant concerns. One
is that they are unable to transduce non-dividing cells (Table 1),
such as post-mitotic neurons and glia, and thus these vectors have
been limited to ex vivo approaches with dividing cells such as
Schwann cells (Girard et al., 2005). The other concern is the ability
of these vectors to integrate into the DNA of the host, which can
lead to disruption of normal cellular gene expression, including inactivation of tumor suppressor genes and activation of oncogenes
resulting in tumorigenesis. Recently, in a clinical trial to treat a rare
X-linked form of severe combined immunodeficiency, three of eleven
treated patients developed T-cell leukemia due to insertions near the
LMO2, BMI1, and CCND2 proto-oncogenes (Hacein-Bey-Abina et al.,
2003). Further work has shown that RV vectors have a predilection
to integrate at or near transcription start sites, within regions of
CpG islands and DNaseI hypersensitive sites present near many
proto-oncogenes (Beard et al., 2007; Derse et al., 2007), explaining
the activation of the LMO2, BMI1, and CCND2 genes following infection of the large number of patient cells used in the SCID-X1 trial.
Finally, the presence of endogenous RV genomes integrated at various
sites within the host cell DNA allows for potential recombination between the vector genome and these endogenous RV sequences. The
outcome of such recombination events, both in terms of the products
they yield and the consequences for the host, has yet to be determined but are likely to be detrimental.
Lentivirus-based vectors
Lentiviral (LV) vectors, derived from human immunodeficiency
virus (HIV), have received considerable interest due to their ability
to infect and integrate into both dividing and non-dividing cells
(Naldini et al., 1996). The structure of the LV particle is similar to
that of RV (enveloped, dsRNA genome), but the virus possesses two
glycoproteins responsible for its entry into cells (gp120 and gp41)
and a more complex genome than standard RV (Fig. 1), encoding numerous functions in addition to the required gag, pol and env gene
products. Similar to RV vectors, LV vectors are produced by transfection of a vector construct containing the therapeutic/reporter gene
into packaging cell lines that provide the structural components of
the virus, or by co-transfection of the vector construct with expression plasmids for gag, pol and env genes. Advantages of LV-based delivery systems (Table 1) include (i) the ease of production facilitated
by commercially available kits and service companies, (ii) excellent
transduction efficiencies of non-dividing cells such as PNS neurons
and spinal cord glia (Finegold et al., 2001; Fleming et al., 2001;
Meunier et al., 2008; Pezet et al., 2006; Wong et al., 2004), and
(iii) the stability of integrated LV genomes and (iv) their extended expression pattern, which persist for many years post transduction. As
260
W.F. Goins et al. / Neurobiology of Disease 48 (2012) 255–270
Fig. 1. Diagrams of the genomes of various viral vectors used in gene therapy approaches to treat peripheral nervous system chronic pain. The type of vector (RV, LV, AAV, AdV,
HSV or HSV-amplicon) is shown along with total genome size, the positions of relevant genes, transcriptional control elements, and viral sequences involved in genome replication and packaging. Production of the replication-defective vectors generally requires special packaging or complementing cell lines to provide deleted essential genes in trans,
as illustrated underneath each vector diagram. Abbreviations: “a”, HSV packaging signal; AAV, adeno-associated virus; AdV, adenovirus; Amp r, ampicillin resistance bacterial
marker gene; ß, HSV early gene; cap, AAV capsid gene; E1–4, adenovirus early genes 1–4; E.coli ori, E.coli origin of replication; gag, group associated antigen capsid gene;
HSV, herpes simplex virus; HSV-ori, HSV origin of replication; ITR, inverted terminal repeat; kb, kilobase; L1–5, adenovirus late genes 1–5; LTR, long terminal repeat; LV, lentivirus; ORF, open reading frame; Ψ, RV/LV packaging signal; pol, polymerase gene; rep, AAV replicase gene; RV, retrovirus; VA, adenovirus small viral encoded RNAs; VSV-G,
vesicular stomatitis virus G envelope glycoprotein.
with standard retroviruses, LV vector integration into the host genome can lead to cell transformation, but this outcome has not been
documented in human clinical trials of LV vectors to date. Unlike standard RV vectors, 50–70% of all LV integration events occur within
genes rather than in upstream regulatory elements (Beard et al.,
2007; Derse et al., 2007), suggesting that integration of these vectors
is more likely to result in insertional inactivation of tumor suppressor
genes rather than in aberrant activation of proto-oncogenes. Early LV
vectors possessed a restricted host-range and suffered from low stability of the purified vector, both of which were remedied by
pseudotyping of the vector with a choice of glycoproteins from
other viruses (VSV, rabies, Mokola, MLV, Ebola, MuLV, measles). LV
pseudotyping with rabies glycoprotein G not only increased the stability of the vector and its host-range, but also enabled retrograde
W.F. Goins et al. / Neurobiology of Disease 48 (2012) 255–270
axonal transport, unlike pseudotyping with VSV-G (Fig. 1), making it
possible to inject LV vectors into the periphery and achieve transduction of DRG and spinal cord neurons (Mazarakis et al., 2001; Wong et
al., 2004). Since HIV, the prototypical LV, is an important human pathogen, there have been serious safety concerns regarding the use of
HIV sequences in gene therapy vectors. Thus the newer LV vectors
are generally designed to minimize such sequences. In addition, LV
vectors have now been derived from equine infectious anemia virus,
which lacks human LV sequences thereby diminishing this concern.
Adenovirus-based vectors
Adenovirus (AdV) is a non-enveloped virus possessing a dsDNA
genome of approximately 40 kb in size that contains a series of
early (E) genes encoding polymerase and enzymatic functions and
late (L) genes for the structural capsid components (Fig. 1). AdV is a
human pathogen that readily infects airway epithelial cells causing
primarily a lytic infection involving lysis of infected cells, release of
new virus particles, and infection of additional cells. The 1st generation, replication-deficient AdV vectors (Fig. 1) were among the first
DNA viruses used in gene transfer/therapeutic approaches. These vectors were deleted for the essential E1 region of the viral genome to
prevent replication, but were able to persist as episomal molecules
without integration into the host genome, a crucial benefit minimizing the risk of tumorigenesis. AdV vectors display good transduction
efficiencies, can mediate very high-level expression of therapeutic
genes in a variety of dividing and non-dividing cell types (Table 1),
including DRG neurons (Glatzel et al., 2000; Mannes et al., 1998;
Watanabe et al., 2006), and can undergo retrograde transport from
peripheral tissues. The 1st generation E1-deleted AdV vectors can accept moderately sized transgene inserts (~5 to 10 kb) which can be
introduced with relative ease using a variety of commercially available kits and the HEK293 complementing cell line that expresses
E1A and E1B, enabling the production of high-titer vector. Early generation AdV vectors continue to express several viral genes in addition to the transgene, resulting in immune recognition of infected
cells and the loss of transgene expression (Varnavski et al., 2005;
Yang et al., 1995). This property limits the use of these vectors in
human clinical studies with the exception of cancer and vaccine trials
where vector-related immunogenicity may actually be beneficial.
While persistent immunogenicity of AdV vectors has hampered efforts to increase the duration of vector-mediated transgene expression by simple vector re-administration (Gonzalez et al., 2007; Yang
et al., 1995), re-dosing has been possible through (i) vector
PEGylation (Croyle et al., 2002), (ii) host immune suppression by
pre-administration of CD40-Ig (Kuzmin et al., 2001), or (iii, #1448)
vector injection into immune privileged sites such as the eye
(Hamilton et al., 2006) or in utero (Lipshutz et al., 2000). The newest
generation AdV vectors, designated “gutless” AdV (Fig. 1), have increased transgene capacity (30–36 kb) and display a reduced inflammatory response compared to previous generations (Alba et al.,
2005). However, these vectors are difficult to grow and purify free
of helper virus to titers suitable for certain in vivo studies; helper
virus contamination induces similar anti-viral responses as earlier
generation vectors. In general, pre-existing immunity or induction
of neutralizing antibodies limits adenoviral vector readministration.
Adeno-associated virus-based vectors
Adeno-associated virus (AAV) is a relatively small, non-enveloped
virus with a dsDNA genome of approximately 5-kb (Fig. 1). Since AAV
is a non-pathogenic human parvovirus that is not currently associated
with any human disease, it is a logical choice for development into a
gene therapy vector for human trials. Similar to RV and LV vectors,
replication-defective AAV vectors are produced by replacement of
the early replication gene (rep) and late capsid genes (cap) with the
therapeutic gene of interest (Fig. 1) and subsequent co-transfection
of this construct into cells along with two plasmids, one encoding
261
the deleted AAV gene functions (rep, cap) and another encoding the
helper functions from AdV (VA1, VA2, E2A, E4) needed to propagate
AAV. Several groups have employed either AdV (Chadeuf et al.,
2000) or HSV as helper (Conway et al., 1997), thereby eliminating
the need to co-transfect three plasmids, in an attempt to produce
AAV vectors more efficiently. To the same end, others have incorporated the AAV helper gene functions into baculovirus (Urabe et al.,
2002) or HSV (Clement et al., 2009). Some of the advantages
(Table 1) of employing AAV include (i) the ability to infect dividing
and non-dividing cells, (ii) stable genome maintenance in nondividing cells, and (iii) very prolonged transgene expression that
has proven extremely useful for a variety of pre-clinical and clinical
applications involving the nervous system. One limitation of AAV is
its relatively small genome size, limiting the vector payload usually
to single small genes of 3–4 kb in size. This impediment has been alleviated to some degree by trans-splicing (Li et al., 2008) and the use
of mini-transgene cassettes (Odom et al., 2008). Transduction of DRG
neurons and spinal cord glia by AAV has been very efficient overall,
regardless of the injection site or method (Fleming et al., 2001;
Glatzel et al., 2000; Towne et al., 2009; Vulchanova et al., 2010). A
concern with AAV vectors is the very high multiplicities required to
achieve transduction that can induce DNA damage responses, vector
integration and insertional mutagenesis. For example, liver transduction with high-titer AAV vectors resulted in a 33% occurrence of hepatocellular carcinoma via integration into chromosome 12 (Donsante
et al., 2007). While it remains difficult to produce high-titer stocks
consistently by co-transfection of multiple plasmids, batches of
>10 14 genome copies with >90% purity are achievable (Lock et al.,
2010). Like Adenovirus, AAV vectors induce neutralizing antibody responses that limit vector re-administration (Zaiss and Muruve, 2005).
However, as with AdV, re-dosing has been achieved with AAV vectors
by (i) reduction of the host immune response using CD40-Ig
(Manning et al., 1998), or (ii) vector administration into immuneprivileged sites (Li et al., 2009). In addition, serotype switching has
shown promising results (Halbert et al., 2000; Riviere et al., 2006).
Herpes simplex virus-based vectors
HSV, a member of the human herpes viruses, is an enveloped virus
containing a dsDNA genome of 152-kb that is composed of two segments, the unique long and unique short segment, each flanked by
inverted terminal repeats (Fig. 1). The large genome encodes over
80 different gene products that are temporally expressed in three distinct waves, immediate early, early, and late. HSV genes are commonly classified as essential for virus replication in cell culture or
accessory, playing a role in virus replication and pathogenesis in
vivo. HSV has many attractive features for gene delivery to the nervous system, most importantly that it readily infects PNS neurons
and can establish a latent or dormant infection in these cells as part
of its natural life cycle. During latency, all of the 80 + HSV lytic
genes are silent with the exception of the latency-associated transcript (LAT) locus (Stevens, 1989), which has evolved a promoter system for long-term expression during latency (Goins et al., 1994).
Other advantages of HSV (Table 1) include (i) its very broad host
cell range providing the opportunity to deliver genes to diverse cell
populations, (ii) a very large transgene capacity capable of accommodating 30–150 kb of foreign DNA, and (iii) the persistence of the its
genome as an extrachromosomal episome in non-dividing cells for
the life of the host (Mellerick and Fraser, 1987). Compared to other
vectors, HSV vectors are more efficient at transducing cells, especially
PNS neurons, and thus fewer vector particles are required at inoculation, which minimizes toxicity and immunogenicity and decreases
the likelihood of clearance of vector-transduced cells. The infectivity
of HSV for neurons is many logs more efficient than that of AAV for
example. One disadvantage of early generation replication-defective
HSV vectors was residual vector-associated toxicity, but elimination
of multiple immediate early genes from the vector genome in 3rd
262
W.F. Goins et al. / Neurobiology of Disease 48 (2012) 255–270
Table 2
Non-opioid gene therapeutic delivery for pain treatment.
Gene
Vector
Delivery route
Model (test)
(A) Neurotrophin gene therapeutic delivery for pain treatment.
BDNF
AAV
i.pi. spinal cord CCI (50% change in MA, 3–4× change in TH PWL, 50% change in MH at 2–8 wpi)
EPO
HSV
s.c. footpad
PDN-STZ (30% decrease in hot plate PWL)
SNL (2 × change in MA at 2–6 wpi; re-dosing works; decrease in c-Fos+)
SNL (30% change in MA and TH PWL at 3–10 dpi)
CCI (2–10 × change in MA 1–6 wpi and 40% change in TH PWL at 3–42 dpi)
HSV
s.c. footpad
i.pi. spinal cord
i.m. tibia
cranialis
s.c. footpad
AdV
AdV
i.t. spinal cord
i.t. spinal cord
Hemilaminectomy (20–50% change in TH PWL at 1–5 wpi)
Hemilaminectomy (20–50% change in TH PWL at 1–5 wpi)
GDNF
GDNF
HGF
HSV
LV
HVJ-lipo
VEGF
FGF2
NGF
PDN-STZ (40% change in hot plate PWL)
(B) Neurotransmitter gene therapeutic delivery for pain treatment
GAD65
AdV
i.n. TG
Formalin (50% change in face rubbing; bicuculline reverses)
GAD65
AAV
i.n. DRG
SNL (2–3 × change in MA and MH at 2–10 wpi)
GAD65
AAV
i.n. sciatic nerve SNK (2 × change in respiration rates at 4–12 wpi)
GAD67
HFV
s.c. footpad
SCI (2–3 × change in MA and 40% change in PWL at 2–6 wpi; re-dosing works)
GAD67
HSV
s.c. footpad
PDN-STZ (3 × change in TH PWL; decrease in Nav1.7)
GAD67
GAD67
GAD67
GAD67
GLT-1
HSV
HSV
HSV
HSV
AdV
s.c. footpad
s.c. footpad
i.m. bladder
i.m. bladder
i.pi. spinal cord
SNL
SNL
SNL
SNL
SNL
(2–3 × change in MA and TH PWL at 1–6 wpi; bicuculline reverses; re-dosing works)
(2 × change in MA at 1–3 wpi)
(40% decrease in NVC at 3 wpi)
(80% decrease in IVP)
(3 × change in MA, 30% change in PWL at 1–3 wpi)
Reference
Eaton et al., 2002
Chattopadhyay et al.,
2009
Hao et al., 2003b
Pezet et al., 2006
Tsuchihara et al., 2009
Chattopadhyay et al.,
2005a
Romero et al., 2001
Romero et al., 2001
Vit et al., 2009
Lee et al., 2007
Kim et al., 2009a
Liu et al., 2008
Chattopadhyay et al.,
2011
Liu et al., 2004
Lee et al., 2007
Miyazato et al., 2009
Miyazato et al., 2010
Maeda et al., 2008
(C) Immune modulatory
IL-10
DNA
IL‐10
DNA
IL‐10
DNA
IL‐10
DNA
IL‐10
DNA-lipo
IL‐10
DNAnano
IL‐10
AdV
IL‐10
AAV
gene therapeutic delivery for pain treatment
i.t. spinal cord
Paclitaxel (3 × change in MA 7–25 dpi; decreased IL-1ß, TNFα in DRG)
i.t. spinal cord
Acid i.m. (no effect on MA with 2 injections of plasmid DNA)
i.t. spinal cord
CCI (2 × change in MA at 4–30 dpi needed 4 injections of plasmid DNA)
i.t. spinal cord
CCI (10× change in MA at 3–43 dpi with 2 injections; 100 μg dose works)
i.t. spinal cord
CCI (10× change in MA at 3–43 dpi with 2 injections; 100 μg dose works)
i.t. spinal cord
CCI (10× change in MA at 1–10 wpi)
Ledeboer et al., 2007
Ledeboer et al., 2006
Milligan et al., 2006a
Sloane et al., 2009
Milligan et al., 2006b
Soderquist et al., 2010
i.t. spinal cord
i.t. spinal cord
Milligan et al., 2005a
Milligan et al., 2005b
IL‐10
IL‐10
IL-2
AAV
HSV
DNA
IL-2
IL-2
IL-4
Iκß
DNA-lipo
AdV
HSV
LV
i.t. spinal cord
s.c. footpad
i.t. vs s.c.
footpad
i.t. spinal cord
i.t. spinal cord
s.c. footpad
i.pi. spinal cord
TNFαsR
HSV
s.c. footpad
TNFαsR
TNFαsR
HSV
HSV
s.c. footpad
s.c. footpad
CCI (10× change in MA and 2–3× change in TH PWL at 4–14 dpi; 50% decrease in IL-1ß)
CCI (decrease in TH PWL)
Zymosan (3–4 × change in MA at 4–11 dpi)
SNL (10× change in MA at 3–84 dpi)
Formalin (40% decreased flinching; 2 × decreased TNFα and p38 MAPK)
Carrageenan (2–6 × change in TH PWL by i.t. vs 2–3× change in TH by footpad 1–6 dpi)
CCI (40% change in TH PWL at 1–7 dpi; lipo ≫ DNA alone; naloxone reverses)
CCI (10–50% change in TH PWL at 1–3 wpi)
SNL (2–4 × change in MA and 40% change in TH PWL 1–4 wpi; decreased c-Fos+, IL-1ß, p38, PGE2)
CCI (20% change in MA, 2 × change in TH PWL at 1–3 wpi; dose-dependent decrease in IL-6, IL1ß, TNFα,
iNOS)
SNL (3 × change in MA and 20–40% change in TH PWL at 1–7 wpi; decrease in p38, IL1ß, PGE2, c-Fos+;
re-dosing)
SCI (2 × change in MA at 1–5 wpi)
Morphine tolerance (20–40% change in hot plate PWL and TF at 2–7 dpi; decreased p38, IL-1ß, TNFα)
(D) Anti-sense gene therapeutic delivery for pain treatment
NMDA-R1 DNA
i.t. spinal cord
Formalin (50% change in flinching; decrease c-Fos+)
NMDA-R1 DNA-lipo i.d. footpad
CFA (4 × change in MA)
Formalin (2 × change in flinching)
NMDA-R1 AAV
i.pi. spinal cord Formalin (2 × change in MA at 3 wpi; 10% change in TH PWL; 2× decrease in flinching)
NMDADNA-lipo i.t. spinal cord
Formalin (2 × decreased Flinching at 7–14 dpi)
R2B
Cav1.2
PNA
i.t. spinal cord
SNL (4 injections 40% change in MA at 2–14 dpi; 1 injection 10%)
Nav1.7
HSV
i.d. footpad
CFA (30% change in PWL; 50% decrease Nav1.7)
Navα
HSV
i.d. footpad
PDN-STZ (1.6 × change in TH PWL and 5.45 change in cold acetone CA at 2 wpi; decrease in Nav1.7/1.8)
GABAB1αR
μ‐OR
μ‐OR
3α-HSOR
GCHI
TLR4
CGRP
HSV
i.d. footpad
Heat (30% change in TH PWL at 4 wpi)
HSV
HSV
DNA-lipo
AAV
DNA
HSV
i.d. footpad
i.d. footpad
i.pi. spinal cord
sciatic nerve
i.t. spinal cord
i.d. footpad
PKCγ
LV
i.t. spinal cord
Loperamide (10–30% change in PWL dependent on [loperamide])
Heat + DAMGO (10–25% change in TH PWL dependent on [DAMGO])
CCI (2 × change in MA; 2–3 × change in TH PWL at 8 μg dose)
SNI (2 × change in MA post-SNI; 3 × change in MA pre-SNI at 10–14 dpi)
Bone cancer (35% change in MA; 1–2× decrease APS at 3–7 dpi)
Heat (2 × change in TH 1–14 wpi)
Capsaicin (3 × change in TH PWL)
Morphine tolerance (40% change in MA; 2 × change in TH PWL at 7–13 dpi; decreased IL-6, IL-1ß, TNFα)
Storek et al., 2008
Zhou et al., 2008
Yao et al., 2002a
Yao et al., 2002b
Yao et al., 2003
Hao et al., 2006
Meunier et al., 2007
Hao et al., 2007
Peng et al., 2006
Sun et al., 2012
Lee et al., 2004
Tan et al., 2010
Garraway et al., 2009
Tan et al., 2005
Fossat et al., 2010
Yeomans et al., 2005
Chattopadhyay et al.,
2012
Jones et al., 2005
Zhang et al., 2008
Jones et al., 2003
Patte-Mensah et al., 2010
Kim et al., 2009b
Lan et al., 2010
Tzabazis et al., 2007
Song et al., 2010
263
W.F. Goins et al. / Neurobiology of Disease 48 (2012) 255–270
Table 2 (continued)
Gene
Vector
Delivery route
Model (test)
Reference
(E) Other gene therapeutic delivery for pain treatment
GlyRα1
HSV
s.c. footpad
Formalin (2 × change in WPS at 7 dpi 10 mM Gly, strychnine reverses)
s.c. footpad
CFA (3 × change in TH PWL at 1–3 dpi 100 mM Gly)
i.m. bladder
RTx (2 × change in ICI at 1.0 mg/kg Gly)
DN-PKCε
HSV
s.c. footpad
Capsaicin (2 × change in TH PWL at 4 dpi)
Goss et al., 2011
Srinivasan et al., 2008
Abbreviations: AAV, adeno-associated virus; AdV, adenovirus; APS, ambulatory pain score; BDNF, brain-derived neurotrophic factor; CA, cold allodynia; Cav1.2, calcium channel,
voltage-dependent, L type, alpha 1 C subunit; CGRP, calcitonin gene related peptide; CNS, central nervous system; CCI, chronic constriction injury; CFA, complete Freund's adjuvant;
DAMGO, [D-Ala2, N-MePhe4, Gly-ol]-enkephalin; DN, dominant-negative; dpi, days post injection; DRG, dorsal root ganglia; EPO, erythropoietin; FGF2, fibroblast growth factor-2;
GABA, γ-aminobutyric acid; GDNF, glial cell-derived neurotrophic factor; GAD, glutamic acid decarboxylase; GLT, glutamate transporter; Gly, Glycine; GCHI, GTP cyclohydrolase I;
HVJ, hemagglutinating virus of Japan; HGF, hepatocyte growth factor; HSV, herpes simplex virus; HSV-amp, herpes simplex amplicon; HFV, human foamy virus; HSOR, hydroxysteroid oxido-reductase; Iκß, inhibitor of NF-κß-associated kinase complex; IL, interleukin; i.a., intra-articular; i.d., intradermal; i.m., intramuscular; i.pi., intraparenchymal spinal
cord; i.t., intrathecal spinal cord; ICI, intercontraction interval; IL, interleukin; iNOS, inducible nitric oxide synthetase; IVP, intravesical pressure; LPS, lipopolysaccharide; LV, lentivirus; MA, mechanical allodynia; MH, mechanical hyperalgesia; Nano, nanoparticles; Nav1.7, voltage-gated sodium channel; NGF, nerve growth factor; NMDA, N-Methyl-D-aspartate; NVC, non-voiding contractions, OR, opioid receptor; PDN, painful diabetic neuropathy; PGE, prostaglandin E; PKC, protein kinase C; PNA, peptide nucleic acid; PWL, paw
withdrawal latency; RTx, resiniferatoxin; s.c., subcutaneous; SCI, spinal cord injury; SNI, spared nerve injury; SNL, spinal nerve ligation; STZ, streptozotocin; TF, tail-flick; TG, trigeminal ganglia; TH, thermal hyperalgesia; TLR, toll-like receptor; TNFαsR, tumor necrosis factor alpha soluble receptor; μg, micrograms; VEGF, vascular endothelial growth factor;
wpi, weeks post injection; WPS, weighted pain score.
generation vectors (Fig. 1) significantly reduced cytotoxicity (Krisky
et al., 1998). These highly defective mutant vectors readily establish
persistence in sensory neurons and in other cell types, thus providing
ideal backbones for the expression of therapeutic genes. HSV possesses a natural promoter system that is uniquely active during latency when all the other viral promoters are repressed (Goins et al.,
1994). This latency-active promoter system has been used to achieve
long-term expression of transgenes in sensory neurons of the PNS
and CNS (Chattopadhyay et al., 2005b; Goins et al., 1999; Palmer et
al., 2000; Perez et al., 2004; Puskovic et al., 2004), key targets for
chronic pain gene therapies. Moreover, the LAP2 component of the
latency-active promoter system can be used in combination with
other promoters, including strong or cell-specific promoters, to
achieve high-level, long-term transgene expression. Another advantage of HSV vectors is that they can be injected directly into a specific
dermatome of tissue where rapid uptake is achieved and infection occurs by retrograde axonal transport in sensory nerves that innervate
the site of injection. For example, inoculation of the skin of the footpad with HSV vectors expressing pre‐proenkephalin (ENK) where
local expression of ENK opiate peptides inhibits nociceptive or neuropathic pain signaling in various animal models of acute and chronic
pain (see Table 2).
As an alternative to using genomic full-length replication defective HSV vectors, several laboratories have employed what have
been termed HSV-amplicon vectors. These vectors (Fig. 1) are simple
to generate as they are based on cloning of the desired therapeutic
gene of interest into an amplicon plasmid that contains an HSV origin
of replication (OriS) and the HSV cleavage and packaging (“a”)
sequence needed for incorporation of the amplicon DNA into newly
synthesized virus particles (Epstein, 2009). The generation of new
HSV particles is achieved by co-transfection of cells with the amplicon
plasmid and either a series of overlapping HSV cosmids or an HSV
genome on a bacterial artificial chromosome (HSV-BAC), both deleted
for the HSV “a” sequences to prevent their incorporation into newly
synthesized virus particles. This procedure yields concatermerized
amplicon DNA packaged into particles with HSV structural proteins
and surface glycoproteins expressed from the cosmid or BAC helper
sequences. Because of the small size of amplicon plasmids and the
overwhelming size of the HSV genome, amplicon vectors can accommodate large amounts of foreign sequences. However, since their
production relies on co-transfection, it has been challenging to produce large-scale, high-titer batches of stable, pure amplicon vectors;
typical titers are in the order of 10 6–10 8 infectious particles/mL compared to 10 10–10 12 PFU/mL for replication defective HSV vectors.
Other concerns are significant residual toxicity and the host immune
response to amplicon vectors which many groups have tried to remedy (Ryan and Federoff, 2009). Nevertheless, HSV-amplicon vectors
have been effectively applied in the treatment of animal models of
chronic pain (Zou et al., 2011).
Gene therapy approaches for the treatment of chronic pain
Neurotrophic/growth factor gene therapy
Growth factor delivery comprised most of the original gene therapeutic studies for pain and were based on many of the initial cell therapy
approaches in which transplanted cells expressing neurotrophins such as
BDNF, NGF or GDNF, either naturally or induced, were employed to reverse pain signaling following intrathecal or intraparenchymal transplant
into the spinal cord of rodents. Both non-viral (HVJ-liposomes) and viral
(AAV, LV and HSV) vectors have been employed to transfer different
neurotrophins or growth factors [e.g. vascular endothelial growth factor
(VEGF), hepatocyte growth factor (HGF), or erythropoietin (EPO)], to
DRG primary neuron nociceptors or cells of the spinal cord. Direct
injection of AAV-BDNF (Eaton et al., 2002) or HVJ-liposomes-HGF
(Tsuchihara et al., 2009) into the parenchyma of the spinal cord improved
both mechanical allodynia and thermal hyperalgesia in the CCI neuropathic pain model (see Table 2A), and similar results were observed
following HSV- or LV-mediated delivery of GDNF in the SNL neuropathic
pain model (Hao et al., 2003b; Pezet et al., 2006) or on administration of
HSV vectors expressing EPO (Chattopadhyay et al., 2009), or VEGF
(Chattopadhyay et al., 2005a) in painful diabetic neuropathy models.
Additionally, AdV vector-mediated expression of FGF2 and NGF reduced
thermal hyperalgesia in animals experiencing hemilaminectomy,
whereas vector expressing the L1 adhesion molecule failed to alter nociceptive behavior (Romero et al., 2001). Although the exact mechanism(s) accounting for these changes to neuropathic nociception still
remain(s) to be resolved, the initial role of these neurotrophins or
growth factors in increasing neuronal survival can not alone account
for the changes observed in the different animal models of neuropathic
pain. Some studies have suggested that increased expression of NGF,
BDNF and GDNF causes changes in CGRP and SP levels (Wang et al.,
2003) and in the levels of ATF3 observed in animal models of neuropathic pain (Pezet et al., 2006). Moreover, increased expression of
growth factors may result in lower levels of cytokine synthesis and release in neuropathic and nociceptive pain models (Jia et al., 2009), all
consistent with roles for these factors besides their growth promoting
activities.
Opioid peptide gene therapy
Initial approaches for the delivery of genes encoding natural opioid
peptides, such as the human pre-proenkephalin (hPPE) gene yielding
both met- and leu-ENK, or the pro-opiomelanocortin (POMC) gene
264
W.F. Goins et al. / Neurobiology of Disease 48 (2012) 255–270
Table 3
Opioid gene therapeutic delivery for pain treatment.
Gene
Vector
Delivery route
Model (test results)
Reference
Enkephalin
Enkephalin
Enkephalin
DNA-GG
HSV
HSV
i.m. bladder
i.d. footpad
s.c. footpad
Chuang et al., 2005
Wilson et al., 1999
Goss et al., 2001
Enkephalin
Enkephalin
HSV
HSV
i.d. footpad
i.m. bladder
Capsaicin (16–43% change in ICI at 4–7 dpi)
Capsaicin (2 × change in PWL)
Formalin (50%, 25, 10% decrease in WPS at 7, 14, and 28 dpi; re-dosing gives 60% reduction; naloxone
reverses)
CFA-arthritis (2 × change in MA, 3 × increased mobility)
Capsaicin (12% decrease in ICI; naloxone reverses)
Enkephalin
Enkephalin
Enkephalin
HSV
HSV
HSV
s.c. footpad
s.c. footpad
i.d. footpad
Enkephalin
Enkephalin
HSV
HSV
i.d. vibrissal pad
i.d. footpad
Enkephalin
Enkephalin
Enkephalin
Enkephalin
Enkephalin
Enkephalin
HSV
HSV
HSV
HSV
HSV
HSV
Pancreas
i.a. knee joint
i.a. knee joint
Pancreas
s.c. footpad
i.m. bladder
Enkephalin
ß-Endorphin
ß‐Endorphin
i.t. spinal cord
i.t. spinal cord
s.c. footpad
ß‐Endorphin
ß‐Endorphin
ß‐Endorphin
ß‐Endorphin
HSV
DNA
DNAMIDGE
DNA-EP
DNA‐EP
DNA‐EP
DNA-SW
ß‐Endorphin
ß‐Endorphin
ß‐Endorphin
DNA-GG
DNA‐GG
AdV
ß‐Endorphin
Endomorphin
Endomorphin
μ-OR
μ‐OR
μ‐OR
μ‐OR
AAV
HSV
HSV
AAV
AAV
AAV
HSV
SNL (3 × change in MA at 1–3 wpi; naloxone reverses)
SNL (2–3× change in MA and TH PWL at 1–5 wpi)
CFA + formalin (4–5 × change in MA, 20–30% change in PWL, 2 × decrease in TF at 1–3 wpi)
CFA + morphine tolerance (30% change in PWL)
Morphine tolerance (TF, PWL; 50% change in morphine ED50)
Morphine tolerance (TF; decrease in morphine ED50)
Loperamide (20% change in TH PWL)
Storek et al., 2008
Wolfe et al., 2007
Hao et al., 2009b
Gu et al., 2005
Chen et al., 2007
Kao et al., 2010
Zhang et al., 2008
i.t. spinal cord
i.t. spinal cord
i.t. spinal cord
i.m. gluteus
maximus
i.m. bladder
s.c. footpad
i.t. + i.pi. spinal
cord
i.t. spinal cord
s.c. footpad
s.c. footpad
sciatic nerve
i.pi. spinal cord
i.pi. spinal cord
i.d. footpad
Braz et al., 2001
Yoshimura et al.,
2001
Bone cancer (90%/60% decrease in APS at 1/3 wpi)
Goss et al., 2002
SNL (2 × change in MA 2–6 wpi; naloxone reverses; 10 × decrease in morphine ED50; re-dosing works) Hao et al., 2003a
PTx (2 × change in PWL at 1–6 wpi)
Yeomans et al.,
2004
CCI (15 × change in MA at 1–6 wpi)
Meunier et al., 2005
Capsaicin (3 × change in PWL 2–20 wpi; naloxone reverses)
Yeomans et al.,
2006
Pancreatitis-DBTC (2 × decrease in Rearing; decrease in spinal cord c-Fos+)
Lu et al., 2007
CFA-arthritis (10 × change in MA, 20% change in TH PWL; decrease in spinal cord c-Fos+)
Lu et al., 2008
CFA-arthritis (20% change in TH PWL)
Pinto et al., 2008
Pancreatitis-DBTC (30% change in TH PWL at 3–9 wpi)
Yang et al., 2008
SNL-morphine (2–3× change in MA; decreased jumping)
Hao et al., 2009a
Capsaicin/RTx (20% change in ICI, 20% decrease in licking, 60% decrease in freezing)
Yokoyama et al.,
2009
CCI (30% change in MA and PWL at 1–5 wpi)
Zou et al., 2011
Formalin (2 × decrease in flinching, TF, PWL)
Lee et al., 2003
CFA (2 × change in MA)
Machelska et al.,
2009
CCI (2–3× change in MA and in TH PWL 7–14 dpi)
Lin et al., 2002
CCI (2 × change in MA and TH PWL at 2–10 dpi)
Wu et al., 2004
CCI (2 × change in MA and TH PWL at 7–14 dpi)
Chen et al., 2008
CFA (2 × change in MA, 20–30% change in TH PWL)
Yamashita et al.,
2009
Acetic Acid (2 × change in ICI)
Chuang et al., 2003
Formalin (40% decrease in flinching, 10% change in TH PWL)
Lu et al., 2002
Carrageenan (2 × change in PWL)
Finegold, et al., 1999
Abbreviations: AAV, adeno-associated virus; AdV, adenovirus; APS, ambulatory pain score; CNS, central nervous system; CCI, chronic constriction injury; CFA, complete Freund's
adjuvant; DBTC, dibutyltin dichloride; dpi, days post infection; ED50, 50% effective dose; EP, electroporation; GG, gene gun; HSV, herpes simplex virus; ICI, intercontraction interval;
i.a., intra-articular; i.d., intra-dermal; i.m., intra-muscular; i.pi., intra-parenchyma spinal cord; i.t., intrathecal spinal cord; MA, mechanical allodynia; MIDGE, non-viral/non-plasmid
minimalistic immunologically defined gene expression; OR, opioid receptor; PTx, pertussis toxin; PWL, paw withdrawal latency; RTx, resiniferatoxin; SW, shockwave; SNL, spinal
nerve ligation; s.c., sub-cutaneous; TF, tail-flick; TH, thermal hyperalgesia; wpi, weeks post infection; WPS, weighted pain score.
responsible for the production of adrenocorticotropic hormone,
melanocyte-stimulating hormone, and ß-endorphin, were also based on
transplantation studies with cells that either naturally express these products (Kim et al., 2009c; Sol et al., 2005) or had been modified to express
hPPE (Hino et al., 2009) or POMC (Beutler et al., 1995). Pohl and coworkers first showed that a tk-defective HSV recombinant injected subcutaneously in the paw transduced DRG neurons for enkephalin expression
(Antunes Bras et al., 1998), and the Glorioso and Wilson laboratories
(Table 3) first used hPPE-expressing HSV vectors in formalin- and
capsaicin-induced nociceptive pain models (Wilson et al., 1999). These
initial studies were followed by additional work with HSV vectors in similar models (Goss et al., 2001; Yeomans et al., 2006; Yokoyama et al.,
2009; Yoshimura et al., 2001). Furthermore, replication-defective genomic HSV vectors expressing ENK (Table 3) have been tested in animal
models of arthritis (Braz et al., 2001; Lu et al., 2008; Pinto et al., 2008),
pancreatitis (Lu et al., 2007; Yang et al., 2008), and pertussis toxininduced models of nociceptive pain (Yeomans et al., 2004), as well as in
the SNL (Hao et al., 2003a, 2009a), CCI (Zou et al., 2011) and bone cancer
(Goss et al., 2002) models of neuropathic pain.
Endorphin (Table 3) has been primarily delivered by plasmid DNA
vectors to treat models of arthritic pain (Machelska et al., 2009;
Yamashita et al., 2009), formalin- or acetic acid-induced nociceptive
pain (Chuang et al., 2003; Lee et al., 2003; Lu et al., 2002), and the
CCI model of neuropathic pain (Chen et al., 2008; Lin et al., 2002;
Wu et al., 2004). In addition, viral vectors such as AAV and AdV
(Table 3) have been used to express endorphins for the treatment
of SNL neuropathic (Beutler et al., 2005) and carrageenan-induced
nociceptive (Finegold et al., 1999) pain. Although an actual
endomorphin gene has not been identified, HSV vectors expressing
endomorphin peptides instead of met- and leu-ENK from an
engineered hPPE construct (Wolfe et al., 2007) proved efficacious
(Table 3) in the treatment of CFA-induced arthritis (Hao et al.,
2009b) and the SNL model of neuropathic pain (Wolfe et al., 2007).
The final gene therapy applications using opioid therapy (Table 3)
have followed a slightly different approach involving expression of
the mu opioid receptor, using AAV (Chen et al., 2007; Gu et al.,
2005; Kao et al., 2010) or HSV (Zhang et al., 2008) vectors where
the pain response in different models could be altered by adjusting
the morphine regimen showing that ectopic production of soluble
mediators (opioid peptides or neurotrophins) is not essential to elicit
a suppressive host response to pain signals.
Neurotransmitter-based gene therapy
Inhibitory amino acid neurotransmitters such as GABA and glycine
play a crucial role in modulating synaptic circuits in the CNS and are
W.F. Goins et al. / Neurobiology of Disease 48 (2012) 255–270
major inhibitors of neuropathic pain signaling in the dorsal horn of
the spinal cord, as suggested by the fact that GABA agonists such as
baclofen are effective in blocking neuropathic pain in some patients.
The enzyme glutamic acid decarboxylase (GAD), present as two different molecular weight forms, GAD67 and GAD65, converts the neurotransmitter glutamate into GABA and thereby represents a
potential pain modulatory effector for use in gene therapy applications. Delivery of the more membrane-associated GAD isoform
(GAD65) using AAV (Kim et al., 2009a; Lee et al., 2007) or AdV (Vit
et al., 2009) resulted in reduced pain in both a neuropathic SNL and
a formalin-induced pain model (Table 2B). The more cytosolic
GAD67 isoform, delivered by a human foamy virus vector (Liu et al.,
2008) or an HSV vector (Chattopadhyay et al., 2011; Lee et al.,
2007; Liu et al., 2004; Miyazato et al., 2009, 2010), was effective in altering nociception in various SCI models (Table 2B), whether injected
into the footpad or the bladder. Like studies (Goss et al., 2001) where
the opioids were expressed (Table 3), some of the GAD67 expression
therapies could be re-administered to achieve even greater nociceptive effects than observed following the first injections (Liu et al.,
2004, 2008). Finally, it was also possible to use bicuculline to reverse
the pain response achieved with GAD65/67 gene therapy (Liu et al.,
2004; Vit et al., 2009) similar to that seen using naloxone in the opioid gene therapy studies (Goss et al., 2001; Hao et al., 2003a;
Yeomans et al., 2006; Yoshimura et al., 2001).
Glutamate is an excitatory amino acid neurotransmitter whose
production is stimulated following inflammation or peripheral nerve
injury. It is released by the DRG nerve termini in the dorsal horn of
the spinal cord and affects signaling via second order neurons
projecting to the brain. Removal of glutamate from the synaptic
cleft within the dorsal horn of the spinal cord can play a major role
in modulating the pain response by keeping its concentration within
a range that prevents over-excitability, a process that may result in
the transition from acute to chronic pain. The glutamate transporter
Glt-1 is down regulated in SNL and CCI models of neuropathic pain.
When expressed in spinal cord astrocytes, it helps maintain the balance of extracellular glutamate and thus represents a promising candidate for pain gene therapy. Indeed, delivery of Glt-1 using AdV
vectors (Table 2B) helped mitigate pain in both the SNL model of neuropathic pain and the carrageenan model of nociceptive pain (Maeda
et al., 2008), providing further evidence that proper maintenance of
excitatory and inhibitory amino acid neurotransmitters is crucial to
blocking chronic pain.
Immuno-modulatory molecule gene therapy
The role of the immune system in causing and exacerbating pain is
a crucial component in the establishment and maintenance of the
chronic pain state. It not only naturally alters nociceptive pain states,
but it also plays a role in neuropathic pain. Numerous modulators of
inflammation have been employed to alter pain, including inhibitory
cytokines such as IL-2, IL-4, and IL-10, and modulators of inflammatory cytokines such as TNFα soluble receptor (TNFαsR), IL-6Ra and IκB,
affecting the activity of TNFα, IL-6 and NFκB, respectively. The majority of this type of gene therapy application (Table 2C) has focused on
the delivery of the anti-inflammatory cytokine IL-10 using plasmid
DNA in CCI (Milligan et al., 2006a, 2006b; Sloane et al., 2009;
Soderquist et al., 2010) and paclitaxel-induced (Ledeboer et al.,
2007) models of neuropathic pain as well as acid-induced nociceptive
pain (Ledeboer et al., 2006). In addition, IL-10 delivery has been performed with viral vectors such as AAV (Milligan et al., 2005b; Storek
et al., 2008) and AdV (Milligan et al., 2005a) in CCI and SNL neuropathic pain models and with HSV in formalin-induced pain (Zhou et
al., 2008). Both plasmid and viral vector delivery methods have
achieved reduced pain levels (Table 2C). IL-2 expressed from nonviral plasmid DNA vectors (Yao et al., 2002a, 2002b) or AdV (Yao et
al., 2003) has also been efficacious in CCI and carrageenan models of
265
neuropathic and nociceptive pain (Table 2C), and HSV vector-based
expression of IL-4 (Table 2C) was shown to reduce pain in an SNL
model of neuropathic pain following direct sub-cutaneous injection
into the footpad (Hao et al., 2006).
TNFαsR expressed from HSV vectors (Table 2C) alleviated chronic
neuropathic pain in SCI and SNL models following footpad injection
(Hao et al., 2007; Peng et al., 2006; Sun et al., 2012). Many genes
that modulate inflammation or alter the pain response are upregulated by the transcription factor NFκB, making this protein a potential target for gene therapy approaches using molecules such as
IκB, a natural inhibitor of NFκB. LV vector-mediated expression of
IκB has been shown to have a dramatic effect on mechanical allodynia
in both the CCI neuropathic and LPS nociceptive pain models
(Table 2) when used to transduce astrocytes via intraparenchymal injection of the spinal cord (Meunier et al., 2007). Because all of the immune modulators mentioned here had an effect on neuropathic as
well as nociceptive pain, it is evident that inflammation plays a role
in the induction or maintenance of chronic neuropathic pain. Many
of the studies expressing the various immune modulatory gene products (Hao et al., 2006, 2007; Ledeboer et al., 2007; Meunier et al.,
2007; Milligan et al., 2005a; Sun et al., 2012; Zhou et al., 2008) demonstrated that expression of the therapeutic molecule not only led to
a change in nociceptive behavior, but it also caused a reduction in
many of the inflammatory mediators such as TNFα, IL-6, IL-1ß, p38MAPK, iNOS that may account for the alleviated pain responses observed. Like prior studies using other gene therapeutics for treating
chronic pain, the HSV vector expressing the TNFα soluble receptor
was able to re-establish a block in the pain response observed in
SNL rats, and this response could be reversed by naloxone treatment.
Anti-sense-based gene therapy
Vectors expressing anti-sense versions of genes involved in the induction or maintenance of pain were first tested by the Wilson and
Yeomans labs. While activation of NMDA-R by glutamate leads to
pain induction, both non-viral plasmid DNA vectors (Lee et al.,
2004; Tan et al., 2005, 2010) and AAV (Garraway et al., 2009) expressing anti-sense NMDA-R in nociceptive pain models led to a reduction in flinching and mechanical allodynia (Table 2D). Similarly,
HSV anti-sense vectors to the GABA-R (Jones et al., 2005) or mu opioid receptor (Jones et al., 2003; Zhang et al., 2008) altered nociceptive
pain paw withdrawal latency (Table 2D). Additionally, HSV or
protein-nucleic acid vectors expressing sodium or calcium channel
anti-sense constructs were efficacious in a CFA nociceptive pain
model (Yeomans et al., 2005) or a SNL neuropathic pain model
(Fossat et al., 2010). A very recent study using HSV vectors expressing
a NaVα anti-sense construct led to reduced expression of both NaV1.7
and NaV1.8 that resulted in changes in both thermal hyperalgesia and
cold allodynia in streptozotocin-treated rats with painful diabetic
neuropathy (Chattopadhyay et al., 2012). HSV vectors expressing
anti-sense to CGRP (Tzabazis et al., 2007) reduced thermal
hyperalgesia in a heat-induced pain model and paw withdrawal latency in a capsaicin-induced model of nociceptive pain (Table 2D). Injection of plasmid DNA vectors expressing anti-sense to TLR4 (Lan et
al., 2010) or alpha-hydroxysteroid oxido-reductase (Patte-Mensah et
al., 2010) resulted in reduced mechanical allodynia and ambulatory
pain scores in behavioral studies of neuropathic pain following direct
injection into the spinal cord (Table 2D). Anti-sense to GTP
cyclohydrolase I delivered by AAV in a SNI model of neuropathic
pain led to decreased mechanical allodynia after sciatic nerve injection (Kim et al., 2009b). Finally, LV mediated PKCγ anti-sense expression (Song et al., 2010) altered morphine-induced mechanical
allodynia and paw withdrawal latency (Table 2D) following intrathecal injection into the sub-arachnoid space. Considering that the antisense approaches have employed vectors expressing complete or
partial anti-sense constructs rather than regions that have previously
266
W.F. Goins et al. / Neurobiology of Disease 48 (2012) 255–270
been determined to reduce expression of the target gene, the overall
results have been quite remarkable.
TRPV1 modulator gene therapy
The vanilloid receptor TRPV1 is a pro-nociceptive cationic channel
activated by the binding of protons, capsaicin, endovanilloids and
noxious heat, indicating an important role in pain signaling. Several
nociceptive pain mediators can up-regulate expression of protein
kinase C-epsilon (PKCε), which phosphorylates TRPV1 in response
to binding of capsaicin or other TRPV1 agonists. HSV vectors expressing a dominant-negative form of PKCε (Table 2E) increased the paw
withdrawal latency following footpad injection of vector in a
capsaicin-induced model of nociceptive pain (Srinivasan et al., 2008).
Recent work by the Glorioso lab has developed a two-vector HSV
co-infection system to select for novel TRPV1-inhibitory genes
(Srinivasan et al., 2007). In the presence of capsaicin, replication of
a TRPV1-expressing HSV vector was blocked as a result of cell death
due to calcium overload. However, replication could be rescued by
expression of a dominant-negative form of TRPV1 from a second
HSV vector. This observation holds promise for the use of HSVbased cDNA libraries (Wolfe et al., 2010) to select for genes that negatively regulate TRPV1 or other ion channels involved in pain
signaling.
Clinical gene therapy trials for pain
The overall goal of all the previously described animal model pain
studies was to identify a vector and therapeutic gene combination that
lead to a consistent reduction in pain behavior in order to take that application to the clinic. However, going from small scale animal studies to
even Phase-I clinical trials requires the consideration of critical issues
such as (i) vector production/purification scale-up, (ii) delivery/administration route, (iii) vector formulation, (iv) toxicity of the vector and/or
therapeutic transgene, (v) recombination of the vector with endogenous
viral sequences present within the host target cells, (vi) reactivation of
resident wild-type virus within the host tissue, (vii) the generation of a
innate or adaptive host response to the vector and/or therapeutic transgene, as well as (viii) overall safety of the therapeutic regimen.
NP2 was developed as a 3rd generation replication-defective HSV
vector for expression of ENK from the hPPE gene. Based on considerable pre-clinical data for this and earlier-generation HSV-ENK vectors
in a variety of pain models (Braz et al., 2001; Goss et al., 2001, 2002;
Hao et al., 2003a, 2009a; Wilson et al., 1999; Yeomans et al., 2004,
2006), NP2 was approved for a dose-escalation Phase-I human clinical trial in patients suffering from moderate to severe intractable
pain due to primary or metastatic cancer (Fink et al., 2011). The vector was injected ten times (100 μL/injection) directly into the
duratome innervating the pain-afflicted region at the site of the
tumor. Study exclusion criteria included patients experiencing HSVrelated disease, those who were undergoing chemo- or radiation‐
therapy or had surgery within the last 6 months, and patients with
immunodeficiencies or who were seropositive for HIV, hepatitis C
and B viruses. Four patients received the lowest dose (10 7 plaque forming units, PFU), while three each received the middle (10 8 PFU) or
highest (10 9 PFU) dose. All were monitored for severe adverse events
(SAEs), other abnormal functions, and their NRS pain scores were
monitored for 4 weeks post-injection (wpi).
The first key observation from this Phase-I study was that none of
the ten patients experienced a treatment-related SAE (Fink et al.,
2011), attesting to the safety of this application using replicationdefective HSV to deliver ENK as safety is the primary endpoint readout of a Phase-I trial. However, efficacy of the therapeutic approach
was also seen in this Phase-I trial with a limited patient population.
Patients receiving the lowest dose (10 7 PFU) showed a reduction in
their NRS pain scores from ~8 down to 6 over the 4-week period.
Moreover, those injected with the middle dose (10 8 PFU) had their
scores drop from 9 to 1 during the first two weeks, followed by an increase to level 4 by 4 weeks. Finally, the highest-dose patients (10 9
PFU) displayed the greatest efficacy, showing NRS values of 8 reduced
to 1 at 2 weeks, with subsequent increases to a maximum score of 2
by the end of the study (Fink et al., 2011). The pattern of alteration
in the patient NRS pain scores closely resembled that the kinetics observed in pre-clinical studies where shut-off of the HCMV promoter
driving expression of the hPPE gene resulted in transient ENK expression waning between 2 and 4 weeks (Goss et al., 2001, 2002). In summary, no SAEs were reported using the NP2 vector system and even in
this limited patient population size this trial showed encouraging efficacy results for chronic pain sufferers. This in turn has led to a
Phase-II trial to assess the maximum tolerated dose in a placebocontrolled dose-escalation study that will also examine readministration of the vector in some patients. Positive efficacy data
results in this Phase-II study would enable the assessment of the
NP2 vector in an even greater patient population to more effectively
assess efficacy. Additionally, a Phase I–II trial for patients with painful
diabetic neuropathy will soon be initiated by Dr. David Fink and
Diamyd Inc. using another replication-defective HSV vector expressing GAD67, based on the pre-clinical studies employing HSV-GAD67
vectors (Chattopadhyay et al., 2011; Lee et al., 2007; Liu et al., 2004;
Miyazato et al., 2009, 2010). Finally, Dr. Linda Watkins and colleagues
in conjunction with Xalud Therapeutics Inc. are preparing to initiate a
Phase-I pain trial using the XT-101 vector system expressing the IL-10
therapeutic gene.
Summary and future directions
The exciting results that have been observed using both non-viral
plasmid and various viral vectors expressing a variety of gene products (neurotrophins, opioids, neurotransmitters, immune modulators, and anti-sense to numerous products) in both nociceptive and
neuropathic pain animal models have led to a Phase-I human trial
using a replication-defective HSV vector expressing ENK. Although
this first gene therapy trial for chronic pain has been a success,
there are ways in which gene transfer and expression can be improved. For example, direct vector injection into animals generally results in transduction of target and non-target cells, dependent on the
vector used (Table 1) and route of administration. Current studies
therefore include efforts to restrict the expression of anti-nociceptive
gene products to the proper target cells using both transductional and
transcriptional targeting.
Another area for improvement is the duration and regulation of
expression of the therapeutic product. In HSV vectors, combination
of the latency promoter LAP2 that provides for long-term expression
(Goins et al., 1994) with other promoters that are normally shut-off
between 14 and 28 days (Chattopadhyay et al., 2005b; Goins et al.,
1999; Palmer et al., 2000; Perez et al., 2004; Puskovic et al., 2004),
has resulted in high-level, long-term transgene expression, but this
has yet to be tested in animal models of pain and the system is
uncontrolled in the fact that once the promoter becomes active, it
can not be shut down. While LAP2 in combination with cell-specific
promoter elements may be responsive to the normal regulatory
mechanisms of the host cell, the therapist again has no control over
the levels or duration of transgene expression following vector delivery. Thus there is a need for novel approaches where it is possible to
activate the therapy only in the presence of when the patient is treated with a safe, non-toxic drug that only affects the target therapy. We
have recently engineered a 3rd generation replication-defective HSV
vector that expresses the ligand-regulated glycine receptor (GlyR), a
chloride ion channel that responds to the inhibitory amino acid neurotransmitter glycine (Goss et al., 2011). Since GlyR is not normally
present on DRG neurons, transduction of DRG neurons with the
HSV-GlyR vector should enable activation of the channel only in
W.F. Goins et al. / Neurobiology of Disease 48 (2012) 255–270
the presence of the exogenously administered ligand glycine. The
HSV-GlyR vector was tested in the formalin-induced and CFAinduced nociceptive pain models following sub-cutaneous footpad
injection and in a resiniferatoxin (RTx)-induced nociceptive pain
model after vector injection into the bladder (Table 2E). In all
models, the injection of vector alone or glycine alone had no effect
on normal nociception. However, administration of glycine at various times post vector injection reduced paw withdrawal latency in
the formalin and CFA models and reduced bladder hyperactivity in
RTx-treated animals. Moreover, the level of anti-nociception
achieved correlated with the doses of both HSV-GlyR vector and
drug, demonstrating a method for regulating the pain response by
drug addition. One complication in advancing this therapeutically
is the presence of GlyR on central projection neurons restricting
the use of a pill or systemic glycine injection to regulate the nociceptive response. However, a mutant form of GlyR has been described
that is no longer responsive to glycine administration but responds
to a related ligand, ivermectin (Lynagh and Lynch, 2010), an FDAapproved drug in widespread use since the late 1980s to eradicate
a devastating parasitic infection in tropical countries (Omura,
2008). Ivermectin can be systemically administered since it has no
effect on endogenous GlyR located centrally and would only act on
vector-expressed mutant GlyR. Additionally, in combination with
vector re-targeting, this system where the addition of a drug results
in activation of the pain therapy can potentially be used to identify
different PNS neuronal subtypes that contribute to either nociceptive or neuropathic pain, or to acute versus chronic pain.
Abbreviations
“a”
HSV packaging signal;
AAV
adeno-associated virus
AdV
adenovirus
APS
ambulatory pain score
Amp r
ampicillin resistance bacterial marker gene
ß
HSV early gene
BDNF
brain-derived neurotrophic factor
CA
cold allodynia
cap
AAV capsid gene
Cav1.2 calcium channel, voltage-dependent, L type, alpha 1C
subunit
CCI
chronic constriction injury
CFA
complete Freund's adjuvant
CGRP
calcitonin gene-related peptide
CNS
central nervous system
DAMGO [D-Ala 2, N-MePhe 4, Gly-ol]-enkephalin
DBTC
dibutyltin dichloride
dpi
days post infection
DN
dominant-negative
dpi
days post injection
DRG
dorsal root ganglia
ED50
50% effective dose
E1–4
adenovirus early genes 1–4
E.coli ori E.coli origin of replication
ENK
enkephalin
env
envelope gene(s)
EP
electroporation
EPO
erythropoietin
FGF2
fibroblast growth factor-2
GABA
γ-aminobutyric acid
GDNF
glial cell-derived neurotrophic factor
GAD
glutamic acid decarboxylase
gag
group associated antigen or capsid gene(s)
GCHI
GTP cyclohydrolase I
GG
gene gun
GLT
glutamate transporter
Gly
Glycine
gp
HCMV
HFV
HGF
HIV
hPPE
HSOR
HSV
HSV-ori
HVJ
IC
ICI
Iκß
IL
i.a.
i.d.
i.m.
i.pi.
i.t.
iNOS
IR
ITR
IVP
kb
L1–5
LAT
LPS
LTR
LV
MA
MIDGE
MH
mL
MLV
MuLV
Nano
Nav1.7
NGF
NMDA
NVC
ORF
Ψ
PDN
PFU
PGE
PKC
PHN
PNA
pol
POMC
PTx
PWL
rep
RTx
RV
SAE
SCI
SNI
SW
SNL
s.c.
SP
STZ
TF
TG
267
glycoprotein
human cytomegalovirus
human foamy virus
hepatocyte growth factor
human immunodeficiency virus
human pre-proenkephalin
hydroxysteroid oxido-reductase
herpes simplex virus
HSV origin of replication
hemagglutinating virus of Japan
interstitial cystitis
intercontraction interval
inhibitor of NF-κß-associated kinase complex
interleukin
intra-articular
intra-dermal
intra-muscular
intra-parenchyma spinal cord
intrathecal spinal cord
inducible nitric oxide synthetase
immune response
inverted terminal repeat
intravesical pressure
kilobase
adenovirus late genes 1–5
HSV latency-associated transcript
lipopolysaccharide
long terminal repeat
lentivirus
mechanical allodynia
non-viral/non-plasmid minimalistic immunologically defined gene expression
mechanical hyperalgesia
milliliters
murine leukemia virus
Moloney murine leukemia virus
nanoparticles
voltage-gated sodium channel
nerve growth factor
N-Methyl-D-aspartate
non-voiding contractions, OR, opioid receptor
open reading frame
RV/LV packaging signal
painful diabetic neuropathy
plaque forming unit
prostaglandin E
protein kinase C
post-herpetic neuralgia
peptide nucleic acid
polymerase gene
pro-opiomelanocortin
pertussis toxin
paw withdrawal latency
AAV replicase gene
resiniferatoxin
retrovirus
severe adverse event
spinal cord injury
spared nerve injury
shockwave
spinal nerve ligation
sub-cutaneous
substance P
streptozotocin
tail-flick
trigeminal ganglia
268
TH
TLR
TNFαsR
Trk
TRPV1
TU
μg
VA
VEGF
VSV-G
VZV
wpi
WPS
W.F. Goins et al. / Neurobiology of Disease 48 (2012) 255–270
thermal hyperalgesia
toll-like receptor
tumor necrosis factor alpha soluble receptor
tyrosine receptor kinase
transient receptor potential vanilloid-1
transducing units
micrograms
adenovirus small viral encoded RNAs
vascular endothelial growth factor
vesicular stomatitis virus G envelope glycoprotein
Varicella zoster virus
weeks post infection
weighted pain score.
Acknowledgments
J.C.G., J.C.C, and W.F.G are inventors of patents related to HSV technology. J.C.G. owns equity in a publicly traded company, Diamyd Medical AB
based in Stockholm, Sweden, that is evaluating HSV gene therapy applications for the treatment of chronic pain.
References
Alba, R., et al., 2005. Gutless adenovirus: last-generation adenovirus for gene therapy.
Gene Ther. 12 (Suppl. 1), S18–S27.
An, K., et al., 2010. Subarachnoid transplantation of immortalized galanin-overexpressing
astrocytes attenuates chronic neuropathic pain. Eur. J. Pain 14, 595–601.
Antunes Bras, J.M., et al., 1998. Herpes simplex virus 1-mediated transfer of
preproenkephalin A in rat dorsal root ganglia. J. Neurochem. 70, 1299–1303.
Basbaum, A.I., Fields, H.L., 1984. Endogenous pain control systems: brainstem spinal
pathways and endorphin circuitry. Annu. Rev. Neurosci. 7, 309–338.
Beard, B.C., et al., 2007. Unique integration profiles in a canine model of long-term
repopulating cells transduced with gammaretrovirus, lentivirus, or foamy virus.
Hum. Gene Ther. 18, 423–434.
Belyanskaya, L., et al., 2009. Effects of carbon nanotubes on primary neurons and glial
cells. Neurotoxicology 30, 702–711.
Bennett, M.I., et al., 2011. Methodological quality in randomised controlled trials of
transcutaneous electric nerve stimulation for pain: low fidelity may explain negative findings. Pain 152, 1226–1232.
Beutler, A.S., et al., 1995. Retrovirus-mediated expression of an artificial betaendorphin precursor in primary fibroblasts. J. Neurochem. 64, 475–481.
Beutler, A.S., et al., 2005. Intrathecal gene transfer by adeno-associated virus for pain.
Curr. Opin. Mol. Ther. 7, 431–439.
Braz, J., et al., 2001. Therapeutic efficacy in experimental polyarthritis of viral-driven
enkephalin overproduction in sensory neurons. J. Neurosci. 21, 7881–7888.
Chadeuf, G., et al., 2000. Efficient recombinant adeno-associated virus production by a
stable rep-cap HeLa cell line correlates with adenovirus-induced amplification of
the integrated rep-cap genome. J. Gene Med. 2, 260–268.
Chattopadhyay, M., et al., 2005a. HSV-mediated gene transfer of vascular endothelial growth
factor to dorsal root ganglia prevents diabetic neuropathy. Gene Ther. 12, 1377–1384.
Chattopadhyay, M., et al., 2005b. Long-term neuroprotection achieved with latencyassociated promoter-driven herpes simplex virus gene transfer to the peripheral
nervous system. Mol. Ther. 12, 307–313.
Chattopadhyay, M., et al., 2009. Neuroprotective effect of herpes simplex virusmediated gene transfer of erythropoietin in hyperglycemic dorsal root ganglion
neurons. Brain 132, 879–888.
Chattopadhyay, M., et al., 2011. Vector-mediated release of GABA attenuates painrelated behaviors and reduces NaV1.7 in DRG neurons. Eur. J. Pain 15, 913–920.
Chattopadhyay, M., et al., 2012. Reduction of voltage gated sodium channel protein in
DRG by vector mediated miRNA reduces pain in rats with painful diabetic neuropathy. Mol. Pain 8, 17.
Chen, S.L., et al., 2007. dsAAV type 2-mediated gene transfer of MORS196A-EGFP into spinal
cord as a pain management paradigm. Proc. Natl. Acad. Sci. U. S. A. 104, 20096–20101.
Chen, K.H., et al., 2008. Intrathecal coelectrotransfer of a tetracycline-inducible, threeplasmid-based system to achieve tightly regulated antinociceptive gene therapy
for mononeuropathic rats. J. Gene Med. 10, 208–216.
Chou, R., et al., 2009. Clinical guidelines for the use of chronic opioid therapy in chronic
noncancer pain. J. Pain 10, 113–130.
Chuang, Y.C., et al., 2003. Gene therapy for bladder pain with gene gun particle
encoding pro-opiomelanocortin cDNA. J. Urol. 170, 2044–2048.
Chuang, Y.C., et al., 2005. Gene gun particle encoding preproenkephalin cDNA produces
analgesia against capsaicin-induced bladder pain in rats. Urology 65, 804–810.
Clement, N., et al., 2009. Large-scale adeno-associated viral vector production using a
herpesvirus-based system enables manufacturing for clinical studies. Hum. Gene Ther.
20, 796–806.
Conway, J.E., et al., 1997. Recombinant adeno-associated virus type 2 replication and
packaging is entirely supported by a herpes simplex virus type 1 amplicon expressing Rep and Cap. J. Virol. 71, 8780–8789.
Croyle, M.A., et al., 2002. PEGylation of E1-deleted adenovirus vectors allows significant gene expression on readministration to liver. Hum. Gene Ther. 13, 1887–1900.
Davidson, B.L., Breakefield, X.O., 2003. Viral vectors for gene delivery to the nervous
system. Nat. Rev. Neurosci. 4, 353–364.
Derse, D., et al., 2007. Human T-cell leukemia virus type 1 integration target sites in
the human genome: comparison with those of other retroviruses. J. Virol. 81,
6731–6741.
Donsante, A., et al., 2007. AAV vector integration sites in mouse hepatocellular carcinoma. Science 317, 477.
Dubinsky, R.M., Miyasaki, J., 2010. Assessment: efficacy of transcutaneous electric
nerve stimulation in the treatment of pain in neurologic disorders (an evidencebased review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 74, 173–176.
Eaton, M.J., et al., 1997. Lumbar transplants of immortalized serotonergic neurons alleviate chronic neuropathic pain. Pain 72, 59–69.
Eaton, M.J., et al., 1999. Transplants of neuronal cells bioengineered to synthesize GABA
alleviate chronic neuropathic pain. Cell Transplant. 8, 87–101.
Eaton, M.J., et al., 2002. Amelioration of chronic neuropathic pain after partial nerve injury by adeno-associated viral (AAV) vector-mediated over-expression of BDNF in
the rat spinal cord. Gene Ther. 9, 1387–1395.
Epstein, A.L., 2009. Progress and prospects: biological properties and technological advances of herpes simplex virus type 1-based amplicon vectors. Gene Ther. 16,
709–715.
Finegold, A.A., et al., 1999. A paracrine paradigm for in vivo gene therapy in the central
nervous system: treatment of chronic pain. Hum. Gene Ther. 10, 1251–1257.
Finegold, A.A., et al., 2001. In vivo control of NMDA receptor transcript level in motoneurons
by viral transduction of a short antisense gene. Brain Res. Mol. Brain Res. 90, 17–25.
Fink, D.J., et al., 2011. Gene therapy for pain: results of a phase I clinical trial. Ann. Neurol. 70, 207–212.
Fishbain, D.A., et al., 2008. What percentage of chronic nonmalignant pain patients
exposed to chronic opioid analgesic therapy develop abuse/addiction and/or
aberrant drug-related behaviors? A structured evidence-based review. Pain Med.
9, 444–459.
Fleming, J., et al., 2001. Adeno-associated virus and lentivirus vectors mediate efficient
and sustained transduction of cultured mouse and human dorsal root ganglia sensory neurons. Hum. Gene Ther. 12, 77–86.
Fossat, P., et al., 2010. Knockdown of L calcium channel subtypes: differential effects in
neuropathic pain. J. Neurosci. 30, 1073–1085.
Garraway, S.M., et al., 2009. siRNA-mediated knockdown of the NR1 subunit gene
of the NMDA receptor attenuates formalin-induced pain behaviors in adult
rats. J. Pain 10, 380–390.
Garry, E.M., et al., 2005. Varicella zoster virus induces neuropathic changes in rat dorsal
root ganglia and behavioral reflex sensitisation that is attenuated by gabapentin or
sodium channel blocking drugs. Pain 118, 97–111.
Girard, C., et al., 2005. Grafts of brain-derived neurotrophic factor and neurotrophin 3transduced primate Schwann cells lead to functional recovery of the demyelinated
mouse spinal cord. J. Neurosci. 25, 7924–7933.
Glatzel, M., et al., 2000. Adenoviral and adeno-associated viral transfer of genes to the
peripheral nervous system. Proc. Natl. Acad. Sci. U. S. A. 97, 442–447.
Goins, W.F., et al., 1994. A novel latency-active promoter is contained within the herpes
simplex virus type 1 UL flanking repeats. J. Virol. 68, 2239–2252.
Goins, W.F., et al., 1999. Herpes simplex virus type 1 vector-mediated expression of
nerve growth factor protects dorsal root ganglion neurons from peroxide toxicity.
J. Virol. 73, 519–532.
Gold, M.S., et al., 1996. Co-expression of nociceptor properties in dorsal root ganglion
neurons from the adult rat in vitro. Neuroscience 71, 265–275.
Gonzalez, S.C., et al., 2007. Readministration of adenoviral gene delivery to dopamine
neurons. Neuroreport 18, 1609–1614.
Goss, J.R., et al., 2001. Antinociceptive effect of a genomic herpes simplex virus-based vector
expressing human proenkephalin in rat dorsal root ganglion. Gene Ther. 8, 551–556.
Goss, J.R., et al., 2002. Herpes vector-mediated expression of proenkephalin reduces
bone cancer pain. Ann. Neurol. 52, 662–665.
Goss, J.R., et al., 2011. HSV delivery of a ligand-regulated endogenous ion channel gene
to sensory neurons results in pain control following channel activation. Mol. Ther.
19, 500–506.
Gu, Y., et al., 2005. Remote nerve injection of mu opioid receptor adeno-associated viral
vector increases antinociception of intrathecal morphine. J. Pain 6, 447–454.
Hacein-Bey-Abina, S., et al., 2003. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302, 415–419.
Halbert, C.L., et al., 2000. Repeat transduction in the mouse lung by using adenoassociated virus vectors with different serotypes. J. Virol. 74, 1524–1532.
Hamilton, M.M., et al., 2006. Repeated administration of adenovector in the eye results
in efficient gene delivery. Invest. Ophthalmol. Vis. Sci. 47, 299–305.
Hao, S., et al., 2003a. Transgene-mediated enkephalin release enhances the effect of
morphine and evades tolerance to produce a sustained antiallodynic effect in neuropathic pain. Pain 102, 135–142.
Hao, S., et al., 2003b. HSV-mediated gene transfer of the glial cell-derived neurotrophic factor provides an antiallodynic effect on neuropathic pain. Mol. Ther.
8, 367–375.
Hao, S., et al., 2006. HSV-mediated expression of interleukin-4 in dorsal root ganglion
neurons reduces neuropathic pain. Mol. Pain 2, 6.
Hao, S., et al., 2007. Gene transfer to interfere with TNFalpha signaling in neuropathic
pain. Gene Ther. 14, 1010–1016.
W.F. Goins et al. / Neurobiology of Disease 48 (2012) 255–270
Hao, S., et al., 2009a. Transgene-mediated enkephalin expression attenuates signs of
naloxone-precipitated morphine withdrawal in rats with neuropathic pain.
Behav. Brain. Res. 197, 84–89.
Hao, S., et al., 2009b. Effects of transgene-mediated endomorphin-2 in inflammatory
pain. Eur. J. Pain 13, 380–386.
Hasnie, F.S., et al., 2007. Further characterization of a rat model of varicella zoster virusassociated pain: relationship between mechanical hypersensitivity and anxietyrelated behavior, and the influence of analgesic drugs. Neuroscience 144, 1495–1508.
Hino, M., et al., 2009. Intrathecal transplantation of autologous macrophages genetically modified to secrete proenkephalin ameliorated hyperalgesia and allodynia following peripheral nerve injury in rats. Neurosci. Res. 64, 56–62.
Hootman, J.M., Helmick, C.G., 2006. Projections of US prevalence of arthritis and associated activity limitations. Arthritis Rheum. 54, 226–229.
Jia, H.B., et al., 2009. Effects of recombinant human erythropoietin on neuropathic pain
and cerebral expressions of cytokines and nuclear factor-kappa B. Can. J. Anaesth.
56, 597–603.
Jones, T.L., et al., 2003. Afferent fiber-selective shift in opiate potency following
targeted opioid receptor knockdown. Pain 106, 365–371.
Jones, T.L., et al., 2005. GABAB receptors on central terminals of C-afferents mediate
intersegmental Adelta-afferent evoked hypoalgesia. Eur. J. Pain 9, 233–242.
Julius, D., Basbaum, A.I., 2001. Molecular mechanisms of nociception. Nature 413,
203–210.
Kao, J.H., et al., 2010. Intrathecal delivery of a mutant micro-opioid receptor activated
by naloxone as a possible antinociceptive paradigm. J. Pharmacol. Exp. Ther. 334,
739–745.
Kim, J., et al., 2009a. Effective neuropathic pain relief through sciatic nerve administration of GAD65-expressing rAAV2. Biochem. Biophys. Res. Commun. 388, 73–78.
Kim, S.J., et al., 2009b. Effective relief of neuropathic pain by adeno-associated virus-mediated
expression of a small hairpin RNA against GTP cyclohydrolase 1. Mol. Pain 5, 67.
Kim, Y.M., et al., 2009c. Reduction of allodynia by intrathecal transplantation of
microencapsulated porcine chromaffin cells. Artif. Organs. 33, 240–249.
Krisky, D.M., et al., 1998. Deletion of multiple immediate-early genes from herpes simplex virus reduces cytotoxicity and permits long-term gene expression in neurons.
Gene Ther. 5, 1593–1603.
Kuraishi, Y., et al., 2004. Effects of the suppression of acute herpetic pain by gabapentin
and amitriptyline on the incidence of delayed postherpetic pain in mice. Life Sci.
74, 2619–2626.
Kuzmin, A.I., et al., 2001. An immunomodulatory procedure that stabilizes transgene
expression and permits readministration of E1-deleted adenovirus vectors. Mol.
Ther. 3, 293–301.
Lan, L.S., et al., 2010. Down-regulation of toll-like receptor 4 gene expression by short
interfering RNA attenuates bone cancer pain in a rat model. Mol. Pain 6, 2.
Ledeboer, A., et al., 2006. Spinal cord glia and interleukin-1 do not appear to mediate
persistent allodynia induced by intramuscular acidic saline in rats. J. Pain 7,
757–767.
Ledeboer, A., et al., 2007. Intrathecal interleukin-10 gene therapy attenuates paclitaxelinduced mechanical allodynia and proinflammatory cytokine expression in dorsal
root ganglia in rats. Brain Behav. Immun. 21, 686–698.
Ledley, F.D., 1995. Nonviral gene therapy: the promise of genes as pharmaceutical
products. Hum. Gene Ther. 6, 1129–1144.
Lee, T.H., et al., 2003. In vivo electroporation of proopiomelanocortin induces analgesia
in a formalin-injection pain model in rats. Pain 104, 159–167.
Lee, I.O., et al., 2004. NMDA-R1 antisense oligodeoxynucleotides modify formalininduced nociception and spinal c-Fos expression in rat spinal cord. Pharmacol. Biochem. Behav. 79, 183–188.
Lee, B., et al., 2007. Constitutive GABA expression via a recombinant adeno-associated virus
consistently attenuates neuropathic pain. Biochem. Biophys. Res. Commun. 357,
971–976.
Li, J., et al., 2008. Protein trans-splicing as a means for viral vector-mediated in vivo
gene therapy. Hum. Gene Ther. 19, 958–964.
Li, W., et al., 2009. Gene therapy following subretinal AAV5 vector delivery is not affected by a previous intravitreal AAV5 vector administration in the partner eye.
Mol. Vis. 15, 267–275.
Lin, C.R., et al., 2002. Electroporation-mediated pain-killer gene therapy for mononeuropathic rats. Gene Ther. 9, 1247–1253.
Lin, C.R., et al., 2010. Sonoporation-mediated gene transfer into adult rat dorsal root
ganglion cells. J. Biomed. Sci. 17, 44.
Lindner, M.D., et al., 2003. Analgesic effects of adrenal chromaffin allografts: contingent
on special procedures or due to experimenter bias? J. Pain 4, 64–73.
Ling, W., et al., 2011. Prescription opioid abuse, pain and addiction: clinical issues and
implications. Drug Alcohol Rev. 30, 300–305.
Lipshutz, G.S., et al., 2000. Reexpression following readministration of an adenoviral vector
in adult mice after initial in utero adenoviral administration. Mol. Ther. 2, 374–380.
Liu, J., et al., 2004. Peripherally delivered glutamic acid decarboxylase gene therapy for
spinal cord injury pain. Mol. Ther. 10, 57–66.
Liu, W., et al., 2008. A novel human foamy virus mediated gene transfer of GAD67 reduces neuropathic pain following spinal cord injury. Neurosci. Lett. 432, 13–18.
Lock, M., et al., 2010. Rapid, simple, and versatile manufacturing of recombinant adenoassociated viral vectors at scale. Hum. Gene Ther. 21, 1259–1271.
Lotze, M.T., Kost, T.A., 2002. Viruses as gene delivery vectors: application to gene function, target validation, and assay development. Cancer Gene Ther. 9, 692–699.
Lu, C.Y., et al., 2002. Gene-gun particle with pro-opiomelanocortin cDNA produces analgesia against formalin-induced pain in rats. Gene Ther. 9, 1008–1014.
Lu, Y., et al., 2007. Treatment of inflamed pancreas with enkephalin encoding HSV-1 recombinant vector reduces inflammatory damage and behavioral sequelae. Mol.
Ther. 15, 1812–1819.
269
Lu, Y., et al., 2008. Joint capsule treatment with enkephalin-encoding HSV-1 recombinant vector reduces inflammatory damage and behavioural sequelae in rat CFA
monoarthritis. Eur. J. Neurosci. 27, 1153–1165.
Lynagh, T., Lynch, J.W., 2010. An improved ivermectin-activated chloride channel receptor for inhibiting electrical activity in defined neuronal populations. J. Biol.
Chem. 285, 14890–14897.
Machelska, H., et al., 2009. Peripheral non-viral MIDGE vector-driven delivery of betaendorphin in inflammatory pain. Mol. Pain 5, 72.
Maeda, S., et al., 2008. Gene transfer of GLT-1, a glial glutamate transporter, into the
spinal cord by recombinant adenovirus attenuates inflammatory and neuropathic
pain in rats. Mol. Pain 4, 65.
Mannes, A.J., et al., 1998. Adenoviral gene transfer to spinal-cord neurons: intrathecal
vs. intraparenchymal administration. Brain Res. 793, 1–6.
Manning, W.C., et al., 1998. Transient immunosuppression allows transgene expression
following readministration of adeno-associated viral vectors. Hum. Gene Ther. 9,
477–485.
Martin, B.I., et al., 2009. Trends in health care expenditures, utilization, and health status
among US adults with spine problems, 1997–2006. Spine (Phila Pa 1976) 34,
2077–2084.
Mazarakis, N.D., et al., 2001. Rabies virus glycoprotein pseudotyping of lentiviral vectors enables retrograde axonal transport and access to the nervous system after
peripheral delivery. Hum. Mol. Genet. 10, 2109–2121.
Mellerick, D.M., Fraser, N., 1987. Physical state of the latent herpes simplex virus genome in a mouse model system: evidence suggesting an episomal state. Virology
158, 265–275.
Meunier, A., et al., 2005. Attenuation of pain-related behavior in a rat model of trigeminal neuropathic pain by viral-driven enkephalin overproduction in trigeminal
ganglion neurons. Mol. Ther. 4, 608–616.
Meunier, A., et al., 2007. Lentiviral-mediated targeted NF-kappaB blockade in dorsal
spinal cord glia attenuates sciatic nerve injury-induced neuropathic pain in the
rat. Mol. Ther. 15, 687–697.
Meunier, A., et al., 2008. Lentiviral-mediated targeted transgene expression in dorsal
spinal cord glia: tool for the study of glial cell implication in mechanisms underlying chronic pain development. J. Neurosci. Methods 167, 148–159.
Milligan, E.D., et al., 2005a. Controlling pathological pain by adenovirally driven spinal
production of the anti-inflammatory cytokine, interleukin-10. Eur. J. Neurosci. 21,
2136–2148.
Milligan, E.D., et al., 2005b. Controlling neuropathic pain by adeno-associated virus driven
production of the anti-inflammatory cytokine, interleukin-10. Mol. Pain 1, 9.
Milligan, E.D., et al., 2006a. Repeated intrathecal injections of plasmid DNA encoding
interleukin-10 produce prolonged reversal of neuropathic pain. Pain 126,
294–308.
Milligan, E.D., et al., 2006b. Intrathecal polymer-based interleukin-10 gene delivery for
neuropathic pain. Neuron Glia Biol. 2, 293–308.
Miyazato, M., et al., 2009. Herpes simplex virus vector-mediated gene delivery of glutamic acid decarboxylase reduces detrusor overactivity in spinal cord-injured rats.
Gene Ther. 16, 660–668.
Miyazato, M., et al., 2010. Suppression of detrusor-sphincter dyssynergia by herpes
simplex virus vector mediated gene delivery of glutamic acid decarboxylase in spinal cord injured rats. J. Urol. 184, 1204–1210.
Moalem, G., Tracey, D.J., 2006. Immune and inflammatory mechanisms in neuropathic
pain. Brain Res. Rev. 51, 240–264.
Naldini, L., et al., 1996. In vivo gene delivery and stable transduction of nondividing
cells by a lentiviral vector. Science 272, 263–267.
Odom, G.L., et al., 2008. Microutrophin delivery through rAAV6 increases lifespan and
improves muscle function in dystrophic dystrophin/utrophin-deficient mice. Mol.
Ther. 16, 1539–1545.
Oliveira, H., et al., 2010. Targeted gene delivery into peripheral sensorial neurons mediated by self-assembled vectors composed of poly(ethylene imine) and tetanus
toxin fragment c. J. Control Release 143, 350–358.
Omura, S., 2008. Ivermectin: 25 years and still going strong. Int. J. Antimicrob. Agents
31, 91–98.
Palmer, J.A., et al., 2000. Development and optimization of herpes simplex virus vectors for
multiple long-term gene delivery to the peripheral nervous system. J. Virol. 74,
5604–5618.
Patte-Mensah, C., et al., 2010. Selective regulation of 3 alpha-hydroxysteroid oxidoreductase expression in dorsal root ganglion neurons: a possible mechanism to
cope with peripheral nerve injury-induced chronic pain. Pain 150, 522–534.
Peng, X.M., et al., 2006. Tumor necrosis factor-alpha contributes to below-level neuropathic pain after spinal cord injury. Ann. Neurol. 59, 843–851.
Perez, M.C., et al., 2004. Comparative analysis of genomic HSV vectors for gene delivery
to motor neurons following peripheral inoculation in vivo. Gene Ther. 11,
1023–1032.
Pezet, S., et al., 2006. Reversal of neurochemical changes and pain-related behavior in a
model of neuropathic pain using modified lentiviral vectors expressing GDNF. Mol.
Ther. 13, 1101–1109.
Pinto, M., et al., 2008. Opioids modulate pain facilitation from the dorsal reticular nucleus. Mol. Cell. Neurosci. 39, 508–518.
Puskovic, V., et al., 2004. Prolonged biologically active transgene expression driven by
HSV LAP2 in brain in vivo. Mol. Ther. 10, 67–75.
Riviere, C., et al., 2006. Long-term expression and repeated administration of AAV type
1, 2 and 5 vectors in skeletal muscle of immunocompetent adult mice. Gene Ther.
13, 1300–1308.
Romero, M.I., et al., 2001. Functional regeneration of chronically injured sensory afferents into adult spinal cord after neurotrophin gene therapy. J. Neurosci. 21,
8408–8416.
270
W.F. Goins et al. / Neurobiology of Disease 48 (2012) 255–270
Ryan, D.A., Federoff, H.J., 2009. Immune responses to herpes viral vectors. Hum. Gene
Ther. 20, 434–441.
Scholz, J., Woolf, C.J., 2002. Can we conquer pain? Nat. Neurosci. 5, 1062–1067 (Suppl.).
Shi, L., et al., 2003. Repeated intrathecal administration of plasmid DNA complexed
with polyethylene glycol-grafted polyethylenimine led to prolonged transgene expression in the spinal cord. Gene Ther. 10, 1179–1188.
Sloane, E., et al., 2009. Immunological priming potentiates non-viral anti-inflammatory
gene therapy treatment of neuropathic pain. Gene Ther. 16, 1210–1222.
Soderquist, R.G., et al., 2010. Release of plasmid DNA-encoding IL-10 from PLGA microparticles facilitates long-term reversal of neuropathic pain following a single intrathecal administration. Pharm. Res. 27, 841–854.
Sol, J.C., et al., 2005. Intrathecal grafting of porcine chromaffin cells reduces
formalin-evoked c-Fos expression in the rat spinal cord. Cell Transplant. 14,
353–365.
Song, Z., et al., 2010. Gene knockdown with lentiviral vector-mediated intrathecal RNA
interference of protein kinase C gamma reverses chronic morphine tolerance in
rats. J. Gene Med. 12, 873–880.
Srinivasan, R., et al., 2007. An HSV vector system for selection of ligand-gated ion channel modulators. Nat. Methods 4, 733–739.
Srinivasan, R., et al., 2008. Protein kinase C epsilon contributes to basal and sensitizing
responses of TRPV1 to capsaicin in rat dorsal root ganglion neurons. Eur. J. Neurosci. 28, 1241–1254.
Stevens, J.G., 1989. Human herpesviruses: a consideration of the latent state. Microbiol.
Rev. 53, 318–332.
Storek, B., et al., 2008. Sensory neuron targeting by self-complementary AAV8 via lumbar
puncture for chronic pain. Proc. Natl. Acad. Sci. U. S. A. 105, 1055–1060.
Sun, J., et al., 2012. Transgene-mediated expression of tumor necrosis factor soluble receptor attenuates morphine tolerance in rats. Gene Ther. 19, 101–108.
Takasaki, I., et al., 2001. Gabapentin antinociception in mice with acute herpetic pain induced
by herpes simplex virus infection. J. Pharmacol. Exp. Ther. 296, 270–275.
Tan, P.H., et al., 2005. Gene knockdown with intrathecal siRNA of NMDA receptor
NR2B subunit reduces formalin-induced nociception in the rat. Gene Ther. 12,
59–66.
Tan, P.H., et al., 2010. Gene knockdown of the N-methyl-D-aspartate receptor NR1 subunit with subcutaneous small interfering RNA reduces inflammation-induced
nociception in rats. Anesthesiology 112, 1482–1493.
Toblin, R.L., et al., 2011. A population-based survey of chronic pain and its treatment
with prescription drugs. Pain 152, 1249–1255.
Towne, C., et al., 2009. Recombinant adeno-associated virus serotype 6 (rAAV2/6)-mediated gene transfer to nociceptive neurons through different routes of delivery.
Mol. Pain 5, 52.
Tsuchihara, T., et al., 2009. Nonviral retrograde gene transfer of human hepatocyte growth
factor improves neuropathic pain-related phenomena in rats. Mol. Ther. 17, 42–50.
Tzabazis, A.Z., et al., 2007. Antihyperalgesic effect of a recombinant herpes virus encoding
antisense for calcitonin gene-related peptide. Anesthesiology 106, 1196–1203.
Urabe, M., et al., 2002. Insect cells as a factory to produce adeno-associated virus type 2
vectors. Hum. Gene Ther. 13, 1935–1943.
Varnavski, A.N., et al., 2005. Evaluation of toxicity from high-dose systemic administration of recombinant adenovirus vector in vector-naive and pre-immunized mice.
Gene Ther. 12, 427–436.
Vit, J.P., et al., 2009. Adenovector GAD65 gene delivery into the rat trigeminal ganglion
produces orofacial analgesia. Mol. Pain 5, 42.
Vulchanova, L., et al., 2010. Differential adeno-associated virus mediated gene transfer
to sensory neurons following intrathecal delivery by direct lumbar puncture. Mol.
Pain 6, 31.
Wang, R., et al., 2003. Glial cell line-derived neurotrophic factor normalizes neurochemical changes in injured dorsal root ganglion neurons and prevents the expression of experimental neuropathic pain. Neuroscience 121, 815–824.
Wang, X., et al., 2005. Gene transfer to dorsal root ganglia by intrathecal injection: effects on regeneration of peripheral nerves. Mol. Ther. 12, 314–320.
Watanabe, T.S., et al., 2006. Adenoviral gene transfer in the peripheral nervous system.
J. Orthop. Sci. 11, 64–69.
Wilson, S.P., et al., 1999. Antihyperalgesic effects of infection with a preproenkephalinencoding herpes virus. Proc. Natl. Acad. Sci. U. S. A. 96, 3211–3216.
Wolfe, D., et al., 2007. Engineering an endomorphin-2 gene for use in neuropathic pain
therapy. Pain 133, 29–38.
Wolfe, D., et al., 2010. A herpes simplex virus vector system for expression of complex
cellular cDNA libraries. J. Virol. 84, 7360–7368.
Wong, L.F., et al., 2004. Transduction patterns of pseudotyped lentiviral vectors in the
nervous system. Mol. Ther. 9, 101–111.
Woolf, C.J., 1996. Windup and central sensitization are not equivalent. Pain 66,
105–108.
Wu, C.M., et al., 2004. Regulated, electroporation-mediated delivery of proopiomelanocortin gene suppresses chronic constriction injury-induced neuropathic pain in rats. Gene Ther. 11, 933–940.
Yamashita, M., et al., 2009. Transfection of rat cells with proopiomeranocortin gene,
precursor of endogenous endorphin, using radial shock waves suppresses inflammatory pain. Spine (Phila Pa 1976) 34, 2270–2277.
Yang, Y., et al., 1995. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J. Virol. 69,
2004–2015.
Yang, H., et al., 2008. Enkephalin-encoding herpes simplex virus-1 decreases inflammation and hotplate sensitivity in a chronic pancreatitis model. Mol. Pain 4, 8.
Yao, M.Z., et al., 2002a. Interleukin-2 gene therapy of chronic neuropathic pain. Neuroscience 112, 409–416.
Yao, M.Z., et al., 2002b. Interleukin-2 gene has superior antinociceptive effects when
delivered intrathecally. Neuroreport 13, 791–794.
Yao, M.Z., et al., 2003. Adenovirus-mediated interleukin-2 gene therapy of nociception.
Gene Ther. 10, 1392–1399.
Yeomans, D.C., et al., 2004. Reversal of ongoing thermal hyperalgesia in mice by a recombinant herpes virus that encodes human preproenkephalin. Mol. Ther. 9, 24–29.
Yeomans, D.C., et al., 2005. Decrease in inflammatory hyperalgesia by herpes vectormediated knockdown of Nav1.7 sodium channels in primary afferents. Hum Gene
Ther 16, 271–277.
Yeomans, D.C., et al., 2006. Recombinant herpes vector-mediated analgesia in a primate model of hyperalgesia. Mol. Ther. 13, 589–597.
Yokoyama, H., et al., 2009. Gene therapy for bladder overactivity and nociception with
herpes simplex virus vectors expressing preproenkephalin. Hum. Gene Ther. 20,
63–71.
Yoshimura, N., et al., 2001. Gene therapy of bladder pain with herpes simplex virus
(HSV) vectors expressing preproenkephalin (PPE). Urology 57, 116.
Younger, J.W., et al., 2011. Prescription opioid analgesics rapidly change the human
brain. Pain 152, 1803–1810.
Zaiss, A.K., Muruve, D.A., 2005. Immune responses to adeno-associated virus vectors.
Curr. Gene Ther. 5, 323–331.
Zeng, J., et al., 2007. Self-assembled ternary complexes of plasmid DNA, low molecular
weight polyethylenimine and targeting peptide for nonviral gene delivery into
neurons. Biomaterials 28, 1443–1451.
Zhang, G., et al., 2008. Enhanced peripheral analgesia using virally mediated gene
transfer of the mu-opioid receptor in mice. Anesthesiology 108, 305–313.
Zhou, Z., et al., 2008. HSV-mediated transfer of interleukin-10 reduces inflammatory
pain through modulation of membrane tumor necrosis factor alpha in spinal cord
microglia. Gene Ther. 15, 183–190.
Zou, W., et al., 2011. Intrathecal herpes simplex virus type 1 amplicon vector-mediated
human proenkephalin reduces chronic constriction injury-induced neuropathic
pain in rats. Mol. Med. Report 4, 529–533.